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ABSTRACT

Hydrazone compounds and pharmaceutical compos1t10ns
including same are disclosed as having antifungal activity.
Such compounds are useful for treating or preventing fungal
conditions in a subject in need thereof by administering
same.
8 Claims, 7 Drawing Sheets
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BISHYDRAZONE-BASED ANTIFUNGAL
AGENTS
RELATED APPLICATIONS
This application claims the benefit of U.S. Provisional
Application Ser. No. 62/359,487, filed Jul. 7, 2016, the entire
disclosure of which is incorporated herein by this reference.
GOVERNMENT INTEREST
This invention was made with govermnent support by
NIH grant A1090048 and NIH grants UOl DA013519,
UL1TR000117 and T32 DA016176; and NIH grants P20
RR020171, CA172379 and CA187273. The Government
has certain rights in the invention.

2
protozoan diseases, such as Trypanosoma brucei gambiense
(West African trypanosomiasis) as well as systemic fungal
infections caused by Pneumocystis jirovecii, often seen in
patients with HIV. Related compounds include symmetrical
bisamidines, (e.g., furimidazoline ), developed principally as
topoisomerase inhibitors for cancer treatments. In addition
to these biscationic compounds, other hydrazone- and guanidine-containing molecules possess a range of promising
biological activities including antituberculosis, anti-HIV,
1o anticonvulsant, anticancer, anti-inflammatory, antimalarial,
antibacterial, and antifungal activities. Recently, bis(N-amidino)hydrazones were reported to inhibit the calcium-dependent serine endoprotease, furin, which activates immature proteins to their functional, mature form.
Accordingly, a continuing need exists for the develop15
ment of specific antifungal agents for the treatment and
prevention of fungal diseases and infections.

TECHNICAL FIELD
SUMMARY
The present disclosure is directed to hydrazone compounds and pharmaceutical compositions including same
having antifungal activity and methods for treating or preventing fungal conditions in a subject in need thereof by
administering same.

20
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BACKGROUND
The emergence of multidrug-resistant bacteria and fungi
as human pathogens warrants a continued focus on the
development of new pharmacophores for the treatment of
these devastating and often fatal infections. The rise of
multidrug-resistant bacteria, such as methicillin-resistant
Staphylococcus aureus (MRSA) and vancomycin-resistant
Enterococci (VRE), adversely affects the efficacy of many
known, standard-of-care, antibacterial agents. Evidence of
the impact of these multidrug-resistant strains appears in a
2011 report from the Centers for Disease Control and
Prevention (CDC) that estimates that the national incidence
of invasive MRSA infections was 80,461 cases and 650
deaths. This mortality rate is among the highest recorded for
bacterial infections. Likewise, listerosis, which is a common
foodborne illness caused by Listeria monocytogenes, represents a serious illness afflicting elderly people, newborns,
and those with impaired immune systems. Estimates suggest
that L. monocytogenes causes 19% of deaths associated with
the consumption of contaminated foods in the United States.
The incidence of invasive fungal infections is also on the
rise due to an increasing population of critically ill patients
as a result of the human immunodeficiency virus (HIV),
systemic diseases such as cancer, and the increasing role of
organ transplantation. The National Healthcare Safety Network (NHSN) at the CDC has reported that Candida spp.
ranked fifth among hospital-acquired pathogens. Candida
spp. fungi have also been reported as the fourth most
common causative pathogens of nosocomial, often fatal
bloodstream infections. Eukaryotic C. albicans share a close
evolutionary relationship as well as many cellular mechanisms with their human hosts and present therapeutic challenges for new treatments for systemic fungal infections.
There is an unquestioned need for new antimicrobials that
selectively inhibit these microorganisms without causing
host toxicity.
Pentamidine represents an archetypical, biscationic antibiotic with a symmetrical structure containing two amidinium functional groups separated by a flexible 1,5-diphenoxypentane spacer. Developed initially as an antiprotozoal
agent, it currently finds applications in both the treatment of
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The presently-disclosed subject matter meets the aboveidentified needs, as will become evident to those of ordinary
skill in the art after a study of information provided in this
document. Advantages of the present disclosure include
antifungal agents and pharmaceutical compositions including same for the treatment or prevention of a fungal condition in a subject in need thereof.
This summary describes several embodiments of the
presently-disclosed subject matter, and in many cases lists
variations and permutations of these embodiments. This
s=ary is merely exemplary of the numerous and varied
embodiments. Mention of one or more representative features of a given embodiment is likewise exemplary. Such an
embodiment can typically exist with or without the
feature(s) mentioned; likewise, those features can be applied
to other embodiments of the presently-disclosed subject
matter, whether listed in this summary or not. To avoid
excessive repetition, this summary does not list or suggest
all possible combinations of such features.
Provided herein, in some embodiments, is an antifungal
composition comprising a compound according to formula
(I):

R

(I)

R

R\ }-linker----( l
HN-N

N-NH

50

55
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or a pharmaceutically acceptable salt thereof, wherein each
R is independently H or a lower alkyl, wherein each R 1 is
independently an amidino or an aryl, and wherein the liuker
comprises at least one aryl. In some embodiments, the liuker
comprises a polycyclic aryl according to formula (II):

\
-0
D'/-~

Z1

\

(II)

j

------z ,,,,
2'

65

wherein Z 1 is selected from the group consisting of a single
bond between the phenyl groups, a lower alkyl linking the
phenyl groups, a R 3 -Y-R3 group, a chalcogen, and com-

US 10,173,968 B2

3

4

binations thereof; wherein Z 2 is selected from the group
consisting of not present, a lower alkyl, a R3 -Y-R3 group,
-C(R4 ) - , ----C(R4 ) 2 - , -N(Rs)-, or a combination
thereof; wherein each R3 is independently a lower alkyl;
wherein each R4 is independently H or a lower alkyl;
wherein Rs is H or a lower alkyl; and wherein Y is a
chalcogen. In some embodiments, the compound is a pharmaceutically acceptable hydrochloride salt.
In one embodiment, the compound is according to formula (III):

X is independently selected from the group consisting of
fluorine, chlorine, and bromine. The compounds having
formula (V) are referred to herein as N-amidino-N'-arylbishydrazones.
Also provided herein, in some embodiments, is a method
for treating a fungal condition, the method comprising
administering to a subject in need thereof a therapeutically
effective amount of a compound according to formula (I):

5

10

R

R\ }-linker----( l

(III)

NHR
2

R HN-<

RHN

}-linker----( }--

HN-N

HN-N

15

2

NHR

N-NH

or a pharmaceutically acceptable salt thereof; wherein each
R 2 is independently selected from the group consisting ofH,
a lower alkyl, an aryl, a substituted lower alkyl, a substituted
aryl, and combinations thereof. The compounds having
formula (III) are referred to herein as bis(N-amidino)hydrazones.
In another embodiment, the compound is according to
formula (IV):

(I)

R

20

N-NH

or a pharmaceutically acceptable salt thereof, wherein each
R is independently H or a lower alkyl, wherein each R 1 is
independently an amidino or an aryl, and wherein the linker
comprises at least one aryl. In some embodiments, the linker
comprises a polycyclic aryl according to formula (II):

\
-0
D-

25

'/-~

Z1

(II)

j

\

------z _,,'
2'

(IV) 30

or a pharmaceutically acceptable salt thereof; wherein Ar is
an aryl group; wherein each X is selected from the group
consisting of electron-withdrawing groups such as, but not
limited to, a halogen, a carbonyl group (e.g., -C(=O)R,
-C(=O)OR, -C(=O)NR2 , or ----CH(=O)), sulfoxide,
sulfone, sulfonate, sulfonamide, a nitro group, a cyano
group, or a combination thereof; and wherein each n is
independently between O and 5, with O representing an
unsubstituted aryl group. In some embodiments, each X is
independently selected from the group consisting of fluorine, chlorine, and bromine. The compounds having formula
(IV) are referred to herein as bis(N-aryl)hydrazones.
In another embodiment, the compound is according to
formula (V):

35
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wherein Z 1 is selected from the group consisting of a single
bond between the phenyl groups, a lower alkyl linking the
phenyl groups, a R3 -Y-R3 group, a chalcogen, and combinations thereof; wherein Z 2 is selected from the group
consisting of not present, a lower alkyl, a R3 -Y-R3 group,
----C(R4 ) - , ----C(R4 ) 2 - , -N(Rs)-, or a combination
thereof wherein each R3 is independently a lower alkyl;
wherein each R4 is independently H or a lower alkyl;
wherein Rs is H or a lower alkyl; and wherein Y is a
chalcogen. In some embodiments, the compound is a pharmaceutically acceptable hydrochloride salt.
In one embodiment, the compound is according to formula (III):

45
(III)

NHR
2

R HN-<
50

RHN

}-linker----(

HN-N

2

}-NHR

N-NH

(V)

55

or a pharmaceutically acceptable salt thereof; wherein Ar is
an aryl group; wherein each X is independently selected
from the group consisting of electron-withdrawing groups
such as, but not limited to, a halogen, a carbonyl group (e.g.,
-C(=O)R, ----C(=O)OR, ----C(=)NR2 , or ----CH(=O)),
sulfoxide, sulfone, sulfonate, sulfonamide, a nitro group, a
cyano group, or a combination thereof; wherein n is between
O and 5, with Orepresenting an unsubstituted aryl group; and
wherein R 2 is selected from the group consisting of H, a
lower alkyl, an aryl, a substituted lower alkyl, a substituted
aryl, and combinations thereof. In some embodiments, each

60

or a pharmaceutically acceptable salt thereof; wherein each
R 2 is independently selected from the group consisting ofH,
a lower alkyl, an aryl, a substituted lower alkyl, a substituted
aryl, and combinations thereof.
In another embodiment, the compound is according to
formula (IV):

(IV)

65

or a pharmaceutically acceptable salt thereof; wherein Ar is
an aryl group; wherein each X is selected from the group

US 10,173,968 B2

5

6

consisting of electron-withdrawing groups such as, but not
limited to, a halogen, a carbonyl group (e.g., -C(=O)R,
-C(=O)OR, -C(=O)NR2 , or ----CH(=O)), sulfoxide,
sulfone, sulfonate, sulfonamide, a nitro group, a cyano
group, or a combination thereof; and wherein each n is
independently between O and 5, with O representing an
unsubstituted aryl group. In some embodiments, each X is
independently selected from the group consisting of fluorine, chlorine, and bromine.
In another embodiment, the compound is according to
formula (IV):

C. After staining with DCFH-DA (20 µg/mL), the samples
were analyzed using a Zeiss Axovert 200M fluorescence
microscope.
FIGS. 4A-B show graphs illustrating a mammalian cell
cytotoxicity of selected bis(N-amidino )hydrazones and
N-amidino-N-aryl-bishydrazones, as well as AmB (as a
control) against (A) A549 cell line and (B) BEAS-2B cell
line.
FIG. 5 shows graphs illustrating IC 50 curves for hERG
inhibition by some representative bis(N-amidino )hydrazones and N-amidino-N-aryl-bishydrazones.

10

DETAILED DESCRIPTION OF THE
DISCLOSURE

(V)
R

XnAr\

R HN

~ linker--{

HN-N

15
2

)--NHR

N-NH

or a pharmaceutically acceptable salt thereof; wherein Ar is
an aryl group; wherein each X is independently selected
from the group consisting of electron-withdrawing groups
such as, but not limited to, a halogen, a carbonyl group (e.g.,
-C(=O)R, ----C(=O)OR, ----C(=O)NR2 , or ----CH(=O)),
sulfoxide, sulfone, sulfonate, sulfonamide, a nitro group, a
cyano group, or a combination thereof; wherein n is between
O and 5, with Orepresenting an unsubstituted aryl group; and
wherein R 2 is selected from the group consisting of H, a
lower alkyl, an aryl, a substituted lower alkyl, a substituted
aryl, and combinations thereof. In some embodiments, each
X is independently selected from the group consisting of
fluorine, chlorine, and bromine.
Additional advantages of the present invention will
become readily apparent to those skilled in this art from the
following detailed description, wherein only the preferred
embodiment of the invention is shown and described, simply
by way of illustration of the best mode contemplated of
carrying out the invention. As will be realized, the invention
is capable of other and different embodiments, and its
several details are capable of modifications in various obvious respects, all without departing from the invention.
Accordingly, the drawings and description are to be regarded
as illustrative in nature, and not as restrictive.
BRIEF DESCRIPTION OF THE DRAWINGS
FIGS. lA-B show schematic views of processes for
synthesizing compounds of the present disclosure. (A) is a
synthetic scheme for the preparation of bis(N-amidino)
hydrazones according to embodiments of the present disclosure. (B) is a synthetic scheme for the preparation of
bis(N-aryl)hydrazones and N-amidino-N'-aryl-bishydrazones according to embodiments of the present disclosure.
FIG. 2 is a bar graph showing the changes in MIC values
of L. monocytogenes ATCC 19115 (strain B), MRSA (strain
C), VRE (strain D), and P. aeruginosa ATCC 27853 (strain
I) treated previously with AMK (green), 7Aa (purple), 4F
(blue), 4D (orange), as well as C. albicans ATCC 10231
treated previously withAmB (yellow), 7Aa (purple), and 4F
(blue) over 15 cycles. Numbers above the bars represent the
passage number when either bacterial or fungal cells developed resistance.
FIG. 3 shows images illustrating the effect of compounds
4F and 7Aa on intracellular ROS production by C. albicans
ATCC 10231. Yeast cells were treated with no drug (negative control), 1 mM of H 2 0 2 (positive control), or 4F and
7Aa, at their 1x and 2x respective MIC values for 1 hat 35°
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The details of one or more embodiments of the presentlydisclosed subject matter are set forth in this document.
Modifications to embodiments described in this document,
and other embodiments, will be evident to those of ordinary
skill in the art after a study of the information provided in
this document. The information provided in this document,
and particularly the specific details of the described exemplary embodiments, is provided primarily for clearness of
understanding and no unnecessary limitations are to be
understood therefrom. In case of conflict, the specification of
this document, including definitions, will control.
While the terms used herein are believed to be well
understood by those of ordinary skill in the art, certain
definitions are set forth to facilitate explanation of the
presently-disclosed subject matter.
Unless defined otherwise, all technical and scientific
terms used herein have the same meaning as is commonly
understood by one of skill in the art to which the invention(s)
belong.
All patents, patent applications, published applications
and publications, GenBank sequences, databases, websites
and other published materials referred to throughout the
entire disclosure herein, unless noted otherwise, are incorporated by reference in their entirety.
Where reference is made to a URL or other such identifier
or address, it understood that such identifiers can change and
particular information on the internet can come and go, but
equivalent information can be found by searching the internet. Reference thereto evidences the availability and public
dissemination of such information.
As used herein, the abbreviations for any protective
groups, amino acids and other compounds, are, unless
indicated otherwise, in accord with their common usage,
recognized abbreviations, or the IUPAC-IUB Commission
on Biochemical Nomenclature (see, Biochem. (1972) 11(9):
1726-1732).
Although any methods, devices, and materials similar or
equivalent to those described herein can be used in the
practice or testing of the presently-disclosed subject matter,
representative methods, devices, and materials are described
herein.
Following long-standing patent law convention, the terms
"a", "an", and "the" refer to "one or more" when used in this
application, including the claims. Thus, for example, reference to "a cell" includes a plurality of such cells, and so
forth.
Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as reaction conditions,
and so forth used in the specification and claims are to be
understood as being modified in all instances by the term
"about". Accordingly, unless indicated to the contrary, the
numerical parameters set forth in this specification and

US 10,173,968 B2
8

7

claims are approximations that can vary depending upon the
or a pharmaceutically acceptable salt thereof. For formula
desired properties sought to be obtained by the presently(I), each R is independently H or a lower alkyl, e.g., a C 1 _6
disclosed subject matter.
alkyl such as a methyl or ethyl group. In one embodiment,
As used herein, the term "about," when referring to a
each R 1 is independently an amidino (----C( NH)NH2 ) or
value or to an amount of mass, weight, time, volume, 5 an aryl group. In another embodiment, at least one R 1 is
independently substituted with one or more electron-withconcentration or percentage is meant to encompass variations of in some embodiments ±20%, in some embodiments
drawing groups such as, but not limited to, one or more
halogens, one or more carbonyl groups (e.g., ----C(=O)R,
±10%, in some embodiments ±5%, in some embodiments
±1%, in some embodiments ±0.5%, and in some embodi----C(=O)OR, ----C(=O)NR2 , or ----CH(=O)), one or more
ments ±0.1 % from the specified amount, as such variations
sulfoxide, one or more sulfone, one or more sulfonate, one
10
are appropriate to perform the disclosed method.
or more sulfonamide, one or more nitro groups, one or more
As used herein, ranges can be expressed as from "about"
cyano groups, or a combination thereof.
one particular value, and/or to "about" another particular
The linker group of formula (I) includes any suitable
moiety having at least one aryl group. For example, in one
value. It is also understood that there are a number of values
disclosed herein, and that each value is also herein disclosed
embodiment, the linker group includes a single aryl, radical,
as "about" that particular value in addition to the value itself. 15 substituted aryl, or aryl derivative. Suitable single aryl linker
For example, if the value "10" is disclosed, then "about 10"
groups include, but are not limited to:
is also disclosed. It is also understood that each unit between
two particular units are also disclosed. For example, if 10
and 15 are disclosed, then 11, 12, 13, and 14 are also
disclosed.
20
As used herein, the term "aryl" or "aryl group" refers to
a substituent derived from an aromatic ring, including, but
not limited to, a phenyl group, pyridyl and other heterocyclic
variants, and/or naphthyl and other polycyclic variants. The
term "substituted aryl" or "substituted aryl group," as used 25
In another embodiment, the linker group is a polycyclic
herein, refers to an aryl group where one or more hydrogen
aryl according to formula (II):
atoms has been replaced by an electron-withdrawing group.
Unless stated otherwise, use of the term "aryl" or "aryl
group" is intended to include "substituted aryl" or "substi(II)
tuted aryl group" throughout the instant disclosure.
30
The term "treat" and "treatment" refer to both therapeutic
treatment and prophylactic or preventative measures,
wherein the object is to prevent or slow down (lessen) an
undesired pathological change or disorder, such as the
development or spread of fungi. For purpose of this disclosure, beneficial or desired clinical results include, but are not 35
limited to, alleviation of symptoms, diminishment of extent
where Z 2 is optionally present in the linker group. Z 1 is a
of disease, stabilized (i.e., not worsening) state of disease,
single bond between the phenyl groups, a lower alkyl linking
delay or slowing of disease progression, amelioration or
the phenyl groups (e.g., a C 1 _6 alkyl), a R3 -Y-R3 group,
palliation of the disease state, and remission (whether partial
or total), whether detectable or undetectable. "Treatment" 40 a chalcogen (e.g., S; 0), or a combination thereof.3 Z 2 , when3
present, is a lower alkyl (e.g., a C 1 _6 alkyl), R -Y-R
can also mean prolonging survival as compared to expected
group, -C(R4 ) - , -C(R4 ) 2 - , -N(R5 ) - , or a combinasurvival if not receiving treatment. Those in need of treattion thereof. Each R 3 is independently a lower alkyl (e.g., a
ment include those already with the condition or disorder as
C 1 _6 alkyl). Each R4 is independently H or a lower alkyl
well as those prone to have the condition or disorder or those
5
in which the condition or disorder is to be prevented.
45 (e.g., a C 1 _6 alkyl). R is H or a lower alkyl (e.g., a C 1 _6
alkyl). Y is a chalcogen, e.g., 0, S. Suitable linker groups
The presently-disclosed subject matter includes antifunaccording to formula (II) include, but are not limited to:
gal compounds having antifungal activity and pharmaceutical compositions including such compounds together with
a pharmaceutically acceptable carrier. The antifungal compounds of the present disclosure are useful as antifungal 50
agents and can inhibit the growth and reproduction of fungal
cells and/or decrease the number of fungi. Accordingly, the
antifungal compounds of the present disclosure can be used
to treat or prevent a fungal condition, e.g., a fungal disease
or infection, in a subject in need thereof. Subject as used 55
herein refer to mammals and in particular to humans and
domestic animals.
The antifungal compound of the instant disclosure
includes a bishydrazone of the general formula (I):
60

R

R

(I)
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HN-N

N-NH
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As will be understood by those skilled in the art, suitable
linker groups are not limited to the specific examples above
and may include any other structure or conformation encompassed by formula (II).

H
45

NH2
HN==<
HN-N

1

In some embodiments, each R in the hydrazone of
formula (I) is an amidino or substituted amidino group,
according to formula (III):

"""N'NHANH,
H

'
50

~
N-HN
>=NH,

(III)

NHR
2
R HN---<

RHN

}-linker---{

HN-N

2
}-NHR

N-NH

or a pharmaceutically acceptable salt thereof. For formula
(III), each R is selected as described above with respect to
formula (I). Additionally, each R 2 is independently H; a
lower alkyl; an aryl; a substituted lower alkyl including, but
not limited to, -CH 2 X, CH 2 CH 2 X, or ----CH 2 CH 2 CH 2 X,
where X includes fluorine, alkoxy (OR), or amino (e.g.,
NHR or NR2 ); a substituted aryl; or a combination thereof.
Suitable compounds according to formula (III) include, but
are not limited to:

65

In other embodiments, each R 1 in the bishydrazone of
formula (I) is an aryl or substituted aryl, according to
formula (IV):
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or a pharmaceutically acceptable salt thereof. For formula
(IV), each R is selected as described above with respect to
formula (I). Ar is an aryl group (e.g., a phenyl group or a
substituted phenyl group); X is an electron-withdrawing
group such as, but not limited to, a halogen (e.g., fluorine,
chlorine, bromine, iodine), a carbonyl group (e.g., ----C(=O)

R, ----C(=O)OR, -C(=O)NR2 , or-CH(=O)), sulfoxide,
sulfone, sulfonate, sulfonamide, a nitro group, a cyano
group, or a combination thereof; and n represents the number of such electron-withdrawing groups on the aryl group,
which can be O to 5, with O representing an unsubstituted
aryl group. In one embodiment, for example, at least one of
the aryl groups is substituted with one or more fluoro or one
or more chloro groups, or both e.g., a fluorinated, chlorinated, difluorinated, dichlorinated, or fluoro-chloro substituted aryl group such as a halogenated phenyl group. Suitable compounds according to formula (IV) include, but are
not limited to:

(IV)

5

10

Fu yCCSDy 0
~

I

N

N/
H

~

H

H

H

I

,;;:?'

N

I

CH3

I

N

,;;:?'

7" '-N
H

H

~

I

F.
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Alternatively, in some embodiments, one R 1 in the hydrazone of formula (I) is an amidino or substitute amidino, and
the other R 1 is an aryl or substituted aryl, according to
formula (V):

30

35

(V)
R

XnAr\

R HN

} - - linker--{

HN-N

2

)---- NHR

N-NH

or a pharmaceutically acceptable salt thereof. For formula
(V), each R is selected as described above with respect to
formula (I). Ar is an aryl group (e.g., a phenyl group); Xis
an electron-withdrawing group such as, but not limited to, a
halogen (e.g., fluorine, chlorine, bromine, iodine), a carbonyl group (e.g., -C(=O)R, -C(=O)OR, ----C(=O)NR2 ,
or ----CH(=O)), sulfoxide, sulfone, sulfonate, sulfonamide,
a nitro group, cyano group, or a combination thereof; and n
represents the number of such electron-withdrawing groups
on the aryl group, which can be O to 5, with O representing
an unsubstituted aryl group. R 2 is H; a lower alkyl; an aryl;
a substituted lower alkyl including, but not limited to,
-CH 2 X, CH 2 CH 2 X, or -CH 2 CH 2 CH 2 X, where X
includes fluorine, alkoxy (OR), or amino (e.g., NHR or
NR2 ); a substituted aryl; or a combination thereof.
The compounds of formula (I) including a linker group
according to one or more of the embodiments disclosed
herein provide increased antibacterial and/or antifungal
activities as compared to existing compounds. For example,
in one embodiment, biscationic pharmacophores, such as the
bis(N-amidino )hydrazones,
bis(N-aryl)hydrazones,
or
N-amidino-N'-aryl-bishydrazones disclosed herein, with
either a flexible or a rigid spacer, provide increased antibacterial and antifungal activities as compared to existing
flexible bisamidines, as well as existing hydrazone- and
guanidine-containing molecules currently found in the lit-
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erature. Additionally, in some embodiments, the compounds
disclosed herein provide antimicrobial activity without or
substantially without developing drug resistance. Furthermore, in some embodiments, the compounds disclosed
herein increase reactive oxygen species (ROS) production.
Accordingly, in some embodiments, the present disclosure includes methods for treating a fungal condition, e.g., a
fungal disease, or fungal infection, by administering to a
subject in need thereof a therapeutically effective amount of
a compound according to formula (I), a pharmaceutically
acceptable salt thereof, or a pharmaceutically acceptable
composition including a compound according to formula (I)
or a pharmaceutically acceptable salt thereof together with a
pharmaceutically acceptable carrier. For example, in one
embodiment, the method for treating a fungal condition
includes administering to a subject in need thereof a therapeutically effective amount of a compound according to any
one or more of formulae (III)-(V), pharmaceutically acceptable salts thereof, or a pharmaceutically acceptable composition including one or more compounds according to formulae (III)-(V) or pharmaceutically acceptable salts thereof
together with a pharmaceutically acceptable carrier.
The phrase "therapeutically effective amount" means an
amount of a compound of the present disclosure that (1)
treats or prevents the particular disease, condition, or disorder, (2) attenuates, ameliorates, or eliminates one or more
symptoms of the particular disease, condition, or disorder, or
(3) prevents or delays the onset of one or more symptoms of
the particular disease, condition, or disorder described
herein. In the case of fungal infection, the therapeutically
effective amount of the drug may be to inhibit the growth
and/or reproduction of fungal cells and/or decrease the
number of fungi and/or relieve to some extent one or more
of the symptoms associated with a fungal condition such as
a fungal disease or infection in a subject.
EXAMPLES

65

The following examples are intended to illustrate certain
preferred embodiments of the invention and are not limiting
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in nature. Those skilled in the art will recognize, or be able
to ascertain, using no more than routine experimentation,
numerous equivalents to the specific substances and procedures described herein.

Design and Chemical Synthesis of Biscationic Compounds with Chemically Non-Identical Termini
Literature approaches for the synthesis of bicationic
agents with two chemically non-identical termini typically
involved the construction of the spacer as the ultimate step.
For example, the coupling of an amidino-substituted naphtha! with a guanidine-substituted benzoic acid secured biscationic esters with an amidinium group at one terminus and
a guandinium group at the other. The synthetic approach that
is reported here differed from this strategy in that a stepwise,
chemoselective modification ofbisaldehydes 1 or bisketones
2 was used to arrive at biscationic systems with different
cationic groups at each terminus. Condensations of one
equivalent ofN-aminoguanidine hydrochloride with IA and
2A led to the efficient production of mono substituted N-amidinohydrazones SA and 6A, respectively (FIG. 18). The
hydrochloride salts of these monocatioinic products were
readily crystallized and thereby were isolated free from
starting materials and suitable for the subsequent synthesis
of the biscationic agents. For example, the subsequent
treatment of SA and 6A with N-arylhydrazines furnished the
desired, biscationic agents 7Aa-Ag and 8Aa, respectively,
which we describe as N-amidino-N'-aryl-bishydrazones
(FIG. 18). Cavallini described the monocationic N-amidinohydrazones as antibacterial agents some years ago, but the
range of organisms and MIC 50 values were, in general,
unimpressive. No effort was made by Cavallini to examine
organisms which represent the most imminent threat to
human health.
The antibacterial and antifungal properties of bis(N-amidino )hydrazones 3 and 4 and N-amidino-N'-aryl-bishydrazones 7 and 8 were evaluated as discussed below.
Antibacterial Activity
To determine if bis(N-amidino)hydrazones and N-amidino-N'-aryl-bishydrazones displayed antibacterial activity,
compounds 3A-8Aa were evaluated against a panel of
Gram-positive (4 strains), Gram-negative (6 strains), and
one mycobacterial strain using the aminoglycoside amikacin
(AMK), the ~-lactam ampicillin (AMP), and the fluoroquinolone ofloxacin (OFX) as positive controls in a concentration range of 0.5-500 µM. The results are provided in Table
1 below.

Example 1
To show the potential of various compounds disclosed
herein, nine symmetrical bis(N-amidino)hydrazones (3A-B
and 4A,C-H) and eight asymmetrical N-amidino-N'-arylbishydrazones (7Aa-Ag and 8Aa) (Scheme 1, FIGS. A-B)
were synthesized, and their antibacterial and antifungal
activities were evaluated against panels of bacterial strains
(four Gram-positive, six Gram-negative, and one mycobacterial) and seven Candida albicans strains. Because the
development of resistance represents a crucial problem in
antimicrobial drug development, the potential of resistance
development by bacteria and fungi against these compounds
was also established. Additionally, the production of reactive
oxygen species (ROS) was measured in yeast cells of some
of these compounds, and the compounds in vitro cytotoxicity as well as the compounds minimal affinity, which is
desired, for the hERG potassium chamiel was determined.
The combination of testing new antimicrobial agents and
early screening for resistance and toxicity represent an
avenue most likely to produce pharmacophores of potential
utility in disease treatment.
Chemical Synthesis ofBiscationic Compounds with Two,
Chemically Identical Termini
To form the biscationic hydrazones of formula (III) with
two N-amidino groups, the carbonyl groups in either bisaldehyde 1 or bisketone 2, which in some cases were in
regiochemically distinct positions in the spacer (e.g., 18,
28, 2H), were modified with N-aminoguanidine hydrochloride to obtain the biscationic products 3 and 4, respectively
(FIG. lA). To form the biscationic hydrazones of formula
(IV) with two N-aryl groups, the carbonyl groups in either
bisaldehyde 1 or bisketone 2, which in some cases were in
regiochemically distinct positions in the spacer (e.g., 18,
28, 2H), were modified with N-arylhydrazines to obtain the
biscationic products 9 and 10, respectively (FIG. 18).
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TABLE 1
MIC values in µg/mL and (µM)" for compounds 3A, B, 4A, C-H, 7Aa-Ag, and 8Aa
against various bacterial strains.

Gram-negative

Gram-positive
Cpd

A

B

c

D

E

F

AMK

3.0-12.2 (3.9-15.6)

3.0 (3.9)

24.5 (31.3)

97.7 (125)

24.5 (31.3)

48.9 (62.5)

AMP

>92.8 (>250)

92.8 (250)

92.8 (250)

92.8 (250)

>92.8 (>250)

>92.8 (>250)

OFX

,;0.2 (,;0.5)

0.4 (1.0)

0.4 (1.0)

2.8 (7.8)

,;0.2 (,;0.5)

,;0.2 (,;0.5)

3A

>198 (>500)

0.4 (1.0)

1.5 (3.9)

0.8 (2.0)

>198 (>500)

>198 (>500)
>198 (>500)

3B

>198 (>500)

0.4 (1.0)

1.5 (3.9)

1.5 (3.9)

>198 (>500)

4A

>212 (>500)

>212 (>500)

>212 (>500)

>212 (>500)

>212 (>500)

52.9 (125)

4C

>219 (>500)

1.7 (3.9)

1.7 (3.9)

0.9 (2.0)

>219 (>500)

>219 (>500)

4D

>226 (>500)

0.5 (1.0)

0.5-0.9 (1.0-2.0)

0.5 (1.0)

>226 (>500)

>226 (>500)

4E

54.9 (125)

27.5 (62.5)

54.9 (125)

1.7 (3.9)

27.5 (62.5)

110 (250)

4F

3.4 (7.8)

<0.2 (<0.5)

0.4-0.9 (1.0-2.0)

0.4 (1.0)

218 (500)

218 (500)

4G

86.8 (250)

86.8 (250)

>173 (>500)

43.4 (125)

173 (500)

>173 (>500)

4H

86.8 (250)

86.8 (250)

>173 (>500)

43.4 (125)

>173 (>500)

>173 (>500)

7Aa

>215 (>500)

0.4-0.9 (1.0-2.0)

0.9 (2.0)

0.9 (2.0)

>215 (>500)

>215 (>500)

7Ab

>235 (>500)

0.9 (2.0)

0.9 (2.0)

0.9 (2.0)

>235 (>500)

>235 (>500)
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TABLE I-continued

MIC values in µg/mL and (µM)" for compounds 3A, B, 4A, C-H, 7Aa-Ag, and 8Aa
against various bacterial strains.
7Ac
7Ad
7Ae
7Af
7Ag
8Aa

>205
>214
13.1
>214
>231
26.6-53.3

(>500)
(>500)
(31.3)
(>500)
(>500)
(62.5-125)

0.8
1.7
3.3
0.9-1.7
3.6
26.6-53.3

(2.0)
(3.9)
(7.8)
(2.0-3.9)
(7.8)
(62.5-125)

3.2
3.3
6.5
1.7
3.6
53.3

(7.8)
(7.8)
(15.6)
(3.9)
(7.8)
(125)

1.6
1.7
0.8-1.6
1.7
3.6
1.7

(3.9)
(3.9)
(2.0-3.9)
(3.9)
(7.8)
(3.9)

>205
>214
6.5-13.1
>214
>231
26.6

(>500)
(>500)
(15.6-31.3)
(>500)
(>500)
(62.5)

>205
>214
209
>214
>231
213

(>500)
(>500)
(500)
(>500)
(>500)
(500)

Gram-negative
Cpd
AMK
AMP
OFX
3A
3B
4A
4C
4D
4E
4F
4G
4H
7Aa
7Ab
7Ac
7Ad
7Ae
7Af
7Ag
8Aa

G
24.5
>92.8
1.4-2.8
>198
>198
26.5
>219
>226
54.9
218
>173
>173
>215
>235
>205
>214
26.1-52.2
>214
>231
213

H
(31.3)
(>250)
(3.9-7.8)
(>500)
(>500)
(62.5)
(>500)
(>500)
(125)
(500)
(>500)
(>500)
(>500)
(>500)
(>500)
(>500)
(62.5-125)
(>500)
(>500)
(500)

24.5
>92.8
5.6-11.3
>198
>198
6.6
>219
>226
27.5
13.6-27.2
173
>173
>215
>235
>205
>214
6.5-13.1
>214
>231
26.6-53.3

K
(31.3)
(>250)
(15.6-31.3)
(>500)
(>500)
(15.6)
(>500)
(>500)
(62.5)
(31.3-62.5)
(500)
(>500)
(>500)
(>500)
(>500)
(>500)
(15.6-31.3)
(>500)
(>500)
(62.5-125)

48.9
>92.8
1.4
>198
>198
0.8
>219
>226
27.5
0.4-0.9
86.8
173
>215
>235
>205
>214
13.1-26.1
>214
>231
213

(62.5)
(>250)
(3.9)
(>500)
(>500)
(2.0)
(>500)
(>500)
(62.5)
(1.0-2.0)
(250)
(500)
(>500)
(>500)
(>500)
(>500)
(31.3-62.5)
(>500)
(>500)
(500)

3.0-6.1
92.8
5.6-11.3
>198
>198
>212
>219
>226
54.9
1.7
86.8-173
21.7-86.8
>215
>235
>205
>214
6.5
>214
>231
26.3-53.3

(3.9-7.8)
12.2 (15.6)
>92.8 (>250)
(250)
(15.6-31.3)
5.6 (15.6)
(>500)
>198 (>500)
(>500)
0.4 (1.0)
(>500)
>212 (>500)
(>500)
0.9 (2.0)
(>500)
0.5 (1.0)
(125)
54.9-110 (125-250)
(3.9)
0.4 (1.0)
(250-500)
>173 (>500)
(62.5-250)
5.4 (15.6)
(>500)
1.7 (3.9)
(>500)
1.8 (3.9)
(>500)
1.6 (3.9)
(>500)
1.7 (3.9)
6.5-13.1 (15.6-31.3)
(15.6)
0.9-1.7 (2.0-3.9)
(>500)
(>500)
1.8 (3.9)
(62.5-125)
213 (500)

aThese antibacterial MIC values were originally determined in µMusing a range of 0.5 to 500 µM. These values are presented into parentheses. The values in µg/mL are presented
for comparison with the antifungal MIC values which were originally determined in µg/mL.
Gram-positive: A= B. subtilis 168, B = L. monocytogenes ATCC 19115, C = MR.SA, D = VRE.
Gram-negative: E = A. baumannii ATCC 19606, F = E. cloacae ATCC 13047, G = E. coli MC1061, H = K. pneumoniae ATCC 27736, I= P. aerngi.nosa ATCC 27853, J = S. enterica
ATCC 14028.
Mycobacterial: K = M. smegmatis MC2-155.
Control antibiotics: AMK = amikacin, AMP = ampicillin, OFX = ofloxacin.

In general, the compounds displayed excellent (MIC
values s0.5-7.8 µM), intermediate (15.6-31.3 µM), or low
(62.5-;;,:500 µM) antibacterial activity against the bacterial
strains tested.
Overall, when analyzing the MIC data obtained against
the Gram-positive bacterial strains (strains A-D), it was
noticed that most of the bis(N-amidino )hydrazones (3A,B,
4C,D, 4F) and N-amidino-N'-aryl-bishydrazones (7Aa-Ad,
and 7Af-Ag) showed excellent antibacterial activity against
Listeria monocytogenes ATCC 19115 (strain B) (MIC <0.57 .8 µM), methicillin-resistant Staphylococcus aureus
(MRSA) (strain C) (MIC=l.0-7.8 µM), and vancomycinresistant enterococcus (VRE) (strain D) (MIC=l.0-7.8 µM).
All of the compounds displayed poor activity against Bacil!us subtilis 168 (strain A), with the exception of compound
4F, which displayed good activity (MIC=7.8 µM) against
this strain. Likewise, compound 7Ae exhibited excellent
antibacterial activity against L. monocytogenes ATCC 19115
(strain B; MIC=7.8 µM) and VRE (strain D; MIC=2.0-3.9
µM) but only moderate antibacterial activity against B.
subtilis 168 (strain A; MIC=31.3 µM) and MRSA (strain C;
MIC=15.6 µM), respectively. Overall, compound 4F was
found to be the most active against Gram-positive bacteria.
Compound 4A exhibited potent activity against P. aeruginosa ATCC 27853 (strain I; MIC=2.0 µM) and moderate
activity against Klebsiella pneumoniae ATCC 27736 (strain
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H; MIC=15.6 µM). Similarly, compound 4F also displayed
excellent antibacterial activities against strain I (MIC=l.02.0 µM) and S. enterica ATCC 14028 (strain J; MIC=3.9
µM), as well as moderate to low activity against strain H
(MIC=31.3-62.5 µM). Additionally, 7Ae showed only moderate antibacterial activities against strain H (MIC= 15 .63 1. 3 µM), strain I (MIC=31.3-62.5 µM), and strain l
(MIC=15.6 µM). Compounds 38, 4C-D, 4F, 7Aa-Ad, and
7Af-Ag exhibited excellent antibacterial activity (MIC values ranging from 1.0-3.9 µM) against M. smegmatis MC2155 (strain K), whereas compounds 411 and 7Ae showed
only moderate activity (15.6-31.3 µM) and compounds 3A,
4A, 4E, 4G, and 8Aa showed low activity (125-500 µM)
against this mycobacterial strain. It is noteworthy to mention
that when compared to clinically relevant antibacterial
drugs, such as AMK (MIC=3.9-125 µM), AMP (MIC;;,:250
µM), and OFX (MICs0.5-31.3 µM), the compounds
reported here showed either superior or comparable antibacterial activity against all bacterial strains tested relative
to these clinical agents.
Antifungal Activity
The antifungal activity of the bis(N-amidino )hydrazones
and N-amidino-N-aryl-bishydrazones was determined
against a panel of seven Candida albicans strains in a
concentration range of 0.5-31.3 µg/mL. The results are
provided in Table 2 below.
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TABLE 2

MIC values in µg/mLa and (µM) for compounds 3A, B, 4A, C-H, 7Aa-Ag, and 8Aa against various C. albicans strains.
C. albicans ATCC strain #

Cpd
AmB
3A
3B
4A
4C
4D
4E
4F
4G
4H
7Aa
7Ab
7Ac
7Ad
7Ae
7Af
7Ag
8Aa

1003a
3.9
7.8
3.9
7.8
7.8
15.6
7.8
1.0
>31.3
>31.3
2.0
2.0
2.0
3.9
7.8
2.0
7.8
15.6

(4.2)
(19.7)
(9.9)
(18.4)
(17.8)
(34.6)
(17.8)
(2.3)
(>90.1)
(>90.1)
(4.6)
(4.1)
(4.7)
(9.1)
(18.7)
(4.5)
(16.8)
(34.3)

1237b
3.9
15.6
3.9
>31.3
7.8
15.6
7.8
2.0
>31.3
31.3
3.9
3.9
7.8
15.6
15.6
3.9
15.6
15.6

(4.2)
(39.5)
(9.9)
(>73.9)
(17.8)
(34.6)
(17.8)
(4.6)
(>90.1)
(90.1
(9.2)
(8.3)
(19.0)
(36.5)
(37.3)
(9.1)
(33.8)
(34.3)

2310c
3.9
>31.3
3.9
3.9
7.8
31.3
7.8
1.0
>31.3
31.3
2.0
3.9
3.9
3.9
15.6
3.9
7.8
15.6

(4.2)
(>79.2)
(9.9)
(9.2)
(17.8)
(69.3)
(17.8)
(2.3)
(>90.1)
(90.1)
(4.6)
(8.3)
(9.5)
(9.1)
(37.3)
(9.1)
(16.8)
(34.3)

2876c
3.9
7.8
3.9
2.0
3.9
3.9
3.9
1.0
>31.3
7.8
2.0
3.9
3.9
7.8
15.6
3.9
15.6
15.6

(4.2)
(19.7)
(9.9)
(4.7)
(8.9)
(8.6)
(8.9)
(2.3)
(>90.1)
(22.5)
(4.6)
(8.3)
(9.5)
(18.3)
(37.3)
(9.1)
(33.8)
(34.3)

10231b
3.9
15.6
3.9
2.0-3.9
7.8
7.8
7.8
1.0-2.0
>31.3
>31.3
2.0
2.0
7.8
7.8
15.6
1.0
7.8
15.6

(4.2)
(39.5)
(9.9)
(4.7-9.2)
(17.8)
(17.3)
(17.8)
(2.3-4.6)
(>90.1)
(>90.1)
(4.6)
(4.1)
(19.0)
(18.3)
(37.3)
(2.3)
(16.8)
(34.3)

64124b
2.0-3.9
>31.3
3.9
2.0
7.8
>31.3
7.8
1.0
31.3
>31.3
3.9
3.9
31.3
15.6
31.3
3.9
31.3
31.3

(2.1-4.2)
(>79.2)
(9.9)
(4.7)
(17.8)
(>69.3)
(17.8)
(2.3)
(90.1)
(>90.1)
(9.2)
(8.3)
(76.2)
(36.5)
(74.9)
(9.1)
(67.8)
(68.7)

90819b
2.0
>31.3
3.9
3.9
7.8
7.8
7.8
2.0
>31.3
>31.3
2.0
3.9
3.9
7.8
15.6
7.8
31.3
15.6

(2.1)
(>79.2)
(9.9)
(9.2)
(17.8)
(17.3)
(17.8)
(4.6)
(>90.1)
(>90.1)
(4.6)
(8.3)
(9.5)
(18.3)
(37.3)
(18.2)
(67.8)
(34.3)

aThese antifungal MIC values were originally determined in Dg/mL using a range of 0.5 to 31.3 µg/mL. The values in µM into parentheses are presented for
comparison with the antibacterial MIC values which were originally determined in µM.
bindicates strains that are resistant to FLC, ITC, and VOR according to ATCC.
cindicates strains that are susceptible to FLC, ITC, and VOR according to ATCC.
Control antifungal agent: ArnB = amphotericin B.

The common antifungal agent amphotericin B (AmB) was
used as a positive control. It was observed that compounds
38, 4F, 7Aa, 7Ab, and 7Af showed excellent antifungal
activities against all fungal strains tested, with 4F showing
superior (MIC=l.0-3.9 µg/mL) activity. Similarly, compound 4A also displayed potent antifungal activities
(MIC=2.0-3.9 µg/mL) against most strains except against C.
albicans ATCC 1003 (MIC=7.8 µg/mL) and C. albicans
ATCC 1237 (MIC=31.3 µg/mL). Compounds 7Ad, 7Ae,
7Ag, and 8Aa showed only moderate fungal growth inhibition (MIC=7.8-15.6 µg/mL) against the majority of the
fungal strains with the exception of C. albicans ATCC
64124 (MIC=31.3 µg/mL for 7Ae, 7Ag, and 8Aa), C.
albicans ATCC 90819 (MIC=31.3 µg/mL for 7Ag), C.
albicans ATCC 1003 (MIC=3.9 µg/mL for 7Ad) and C.
albicans ATCC 2310 (MIC=3.9 µg/mL for 7Ad). Compounds 7Ac also exhibited excellent growth inhibition
against most of the fungal strains tested, except against C.
albicans ATCC 10231 (moderate activity, MIC=7.8 µg/mL)
and C. albicans ATCC 64124 (poor activity, MIC=31.3
µg/mL). It is important to emphasize that most of the
bis(N-amidino )hydrazones and N-amidino-N-aryl-bishydrazones displayed either superior or comparable antifungal
activities against the majority of the fungal strains tested,
when compared to the clinically relevant antifungal agents,
AmB (MIC=2.0-3.9 µg/mL).
SAR Analysis.
Variations in SAR outcomes for compounds studied as
antibacterial or as antifungal agents was expected given that
bacteria are prokaryotic organisms and fungi are eukaryotic
organisms.
Based upon the antibacterial and antifungal results presented in Tables 1 and 2, it was determined that with respect
to bis(N-amidino )hydrazones, linkers comprised of a single
phenyl ring, regardless of its substitution pattern (para or
meta, as in compounds 4G and 4H, respectively), displayed
diminished but not non-existent antimicrobial activity as
compared to the other linkers disclosed herein. Additionally,
comparing the MIC value profiles of compounds 3A and 4A
as well as 7Aa and 8Aa, which only differ by the absence or
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presence of a methyl group on the carbons alpha to the
phenyl rings indicated that the methyl group diminished
antibacterial activity of these compounds relative to cases
where the carbons alpha to the phenyl rings contained a
hydrogen. However, the presence of the methyl group
appeared beneficial in terms of antifungal activity. For
example, compound 4A was overall a much better antifungal
agent than compound 3A. Turning to the antibacterial MIC
values for compounds 3A and 38, it was observed that they
were about equivalent in all cases, except against strain K
where the MIC value for compound 38 (MIC=l µM) was
much lower than that for compound 3A (MIC>500 µM).
From these data, it was deduced that the substitution patterns
of the biphenyl linkers had minimal effects on antibacterial
activity. However, the substitution patterns of the biphenyl
linkers were found to have a substantial effect on antifungal
activity. For example, compound 38 was a much better
antifungal agent than compound 3A.
With respect to the length of the flexible, linear, alkyl
spacer between the two phenyl rings, comparing the MIC
values of compounds 4A, 4C, and 4D, once again showed
opposing trends in antibacterial and antifungal activities. In
particular, increasing the length of the flexible alkyl linker
between the two phenyl rings resulted in a decrease in
antibacterial MIC values, whereas this same increase in the
length of the linker resulted in an increase in antifungal MIC
values. As to rigidity of the linker, by contrasting the MIC
value profile of compound 4C containing a flexible linker to
that of compound 4F containing a rigid linker, it was
concluded that introducing rigidity in the linker was beneficial for antimicrobial activity. In contrast to rigidity, a
comparison of the MIC value profiles of compounds 4C and
4E indicated that replacing the methylene bridging the two
phenyl groups of the linker with an oxygen atom had no
effect on antifungal activity, but was detrimental to antibacterial activity.
Next, by comparing compounds 7Aa-7Ag, it was
observed that the nature of the substituent in the ortho
position of the mono-substituted aryl group of compounds
7Aa and 7Ab did not affect antibacterial or antifungal
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activity, whereas the nature of the substituent in the para
position of the mono-substituted aryl group of compounds
7Ac-7Ae had the opposing effects on antibacterial
(CN>halogen) and antifungal (halogen>CN) activity. It was
also observed that the o,p-difluorinated and o,p-dichlorinated aryl moieties of compounds 7Af and 7Ag had similar
overall antibacterial activity, but different antifungal activity,
in which the o,p-difluorinated group possessed improved
antifungal activity. Finally, with regard to the effect of
substitution pattern of the aryl ring (ortho versus paramonosubstituted versus ortho,para-disubstituted) on antimicrobial activity, a comparison of the activity resulting from
different chlorination patterns in compounds 7Aa (ortho ),
7Ad (para), and 7Ag (o,p-diCl), indicated that these changes
had minimal effects on antibacterial activity but substantial
effects on antifungal activity. The a-chlorinated N-amidinoN-aryl-bishydrazone was superior to the p-chlorinated analog, which in turn was much better than o,p-dichlorinated
analog.
Development of Bacterial and Fungal Resistance Studies
The emergence of antibiotic resistance by microbes is an
inevitable process; however, the frequency at which resistance develops varies from one antibiotic to another. It is
critical to assess the ability of new antimicrobials to evade,
as long as possible, the development of bacterial and fungal
resistance early in the development process.
To establish if the bis(N-amidino )hydrazones and N-amidino-N-aryl-bishydrazones evaded resistance in bacteria, a
multi-step resistance selection experiment was performed
with compounds 4D, 4F, and 7Aa and with AMK as a
reference drug against four bacterial strains (FIG. 2). L.
monocytogenes ATCC 19115 (strain B), MRSA (strain C),
VRE (strain D), and P. aeruginosa ATCC 27853 (strain I)
were exposed to sub-inhibitory concentrations of compounds 4D, 4F, 7Aa, and AMK, and were sub-cultured for
15 serial passages to determine if any increase in MIC values
occurred for each compounds against the strains tested. L.
monocytogenes ATCC 19115 (strain B), MRSA (strain C),
VRE (strain D), and P. aeruginosa ATCC 27853 (strain I)
did not develop resistance to compound 4F, as established by
the fact that the relative MIC values increased only by
one-fold after 15 serial passages. Likewise, strains Band D
did not develop resistance to compound 7Aa, but strains C
and I developed resistance to this compound after twelve
serial passages. In contrast, the rapid development of resistance to compound 4D was observed in strains C and D with
a 16-fold increase in MIC values after fifteen serial passages.
This resistance development against compound 4D was also
observed in strains B and I, where increases in relative MIC
values by 8- and 4-folds were observed after 15 passages.
Interestingly, in strains D and I, resistance to the control
antibiotic, AMK, was also observed after 3 and 5 passages,
respectively, whereas in strains C and B, resistance developed after 12 and 15 passages, respectively. Overall, these
results indicate that there is a low probability of emergence
of resistance to the antifungal, biscationic compounds 4F
and 7Aa.
The potential development of drug resistance in C. albicans ATCC 10231 to anti fungal compounds 7Aa and 4 F was
investigated. The results indicated that C. albicans ATCC
10231 was unable to develop drug resistance to either 7Aa
or 4F, despite repeated treatments with sub-MIC drug concentrations. Only a slight 2-fold shift in relative MIC values
was observed after 13 passages. These results also suggested
the appearance of drug resistance by fungi to the antifungal
compounds of the present disclosure is highly unlikely, a
particularly desirable outcome.

Measurement of ROS Induction in Fungal Cells
Various antifungal drugs, such as AmB and miconazole,
as well as the antifungal agents of the present disclosure,
were shown to mediate their inhibitory effect by inducing
intracellular ROS production. Universally, eukaryotic cells
produce basal amount of ROS in mitochondria as a byproduct of cellular metabolism. In response, the cellular enzymatic antioxidants, including superoxide dismutase and glutathione peroxidase, scavenge ROS in cells. However,
overproduction of deleterious ROS perturbs the delicate,
intracellular equilibrium between ROS production and scavenging, and results in cellular damage.
To show the ability of compounds 4F and 7Aa to alter
ROS production in C. albicans ATCC 10231 (strain A), a
fluorescent-based assay was performed using a 2',7'-dichlorodihydrofluorescein diacetate (DCFH-DA) dye. It was
found that treatment of C. albicans ATCC 10231 (strain A)
with compounds 4F and 7Aa at their lx and 2xMIC values
significantly increased intracellular ROS production in this
fungal strain (FIG. 3). As expected, an H 2 0 2 positive control
(at 1 mM) also induced ROS production in yeast cell,
whereas no ROS induction was observed with untreated
yeast cells (negative control).
Cytotoxicity
Another important aspect to consider during the development of antimicrobial agents is their potential toxicity
towards manmialian cells. Having established the potent
antimicrobial activities of the bis(N-amidino )hydrazones
and N-amidino-N'-aryl-bishydrazones against bacteria and
fungi, the toxicity profile of these compounds was determined against two mammalian cell lines (A549 and BEAS28; FIGS. 4A-B). The majority of the compounds showed
dose-dependent toxicity with IC 50 values of 1.95-3.9 µg/mL
against these cell lines. Compounds 38, 7Ac, 7Ad, and 7Af
with antibacterial MIC values of <0.4-3.3 µg/mL, displayed
good IC 50 values of 7.8-15.6 µg/mL against both mammalian cell lines. It is important to remember that compounds
7Ac and 7Af also displayed strong antifungal MIC values.
hERG Inhibition Assay
The human Ether-a-go-go related gene (hERG) encodes a
voltage-gated potassium channel that plays an essential role
in regulating heart rhythm. Inhibition of the potassium
channel coded by hERG disrupts the heart rhythm and may
lead to death. Recently, clinically used drugs (e.g., terfendadine and cisapride) were withdrawn from the market due
to their interaction with hERG. Currently, the U.S. Food and
Drug Administration (FDA) and the European Medicines
Agency (EMA) require testing ofhERG affinity for potential
novel drugs during the early stage of the drug development.
A [3 H]-dofetilide competition binding assay using HEK293 cell membranes stably expressing hERG channel was
performed to evaluate interaction of the most potent bis(Namidino )hydrazones and N-amidino-N'-aryl-bishydrazones
with hERG (FIG. 5). Compounds exhibiting IC 50 values of
> 10 µMare considered to have desirable, low affinity for the
hERG channel. Compounds displaying IC50 values in the
range of 1-10 µM are considered moderate inhibitors,
whereas compounds exhibiting IC 50 values of <l µM are
considered to have undesirable, high affinity for the hERG
channel. The majority of the compounds of the present
disclosure displayed IC 50 values within the acceptable range
of 1-10 µM (FIG. 5) against the hERG channel. For
example, the p-fluorophenyl and the 2,4-difluorophenyl
groups in compounds 7Ac and 7Af displayed only moderate
inhibition of the hERG channel with IC 50 values of
3.29±0.625 µMand 2.24±0.701 µM, respectively. Strikingly,
both of these compounds displayed excellent antifungal
activities and also exerted low mammalian cell toxicity.
Similarly, compounds 4F and 7Aa also displayed moderate
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inhibition ofhERG channel with IC 50 values of 1.12±0.317
µM and 1.14±0.267 µM, respectively; however, they displayed some toxicity against mammalian cells. Therefore, it
was concluded, once again, that compounds 7Ac and 7Af
are the most promising N-amidino-N'-aryl-bishydrazones.
5

Example 2
Materials and Instrumentation.
Chemicals were purchased from Sigma-Aldrich-Fluka
(PO Box 14508 St. Louis, Mo., 63178, USA), Matrix, Inc.
(131 Pontiac Business Center Dr., Elgin, S. C., 29045,
USA), and Thermo-Scientific (7383 Empire Dr., Florence,
Key., 41042, USA), or were synthesized according to literature procedures, unless otherwise noted. Solvents were
used from commercial vendors without further purification
unless otherwise noted. Nuclear magnetic resonance (NMR)
spectra were determined in DMSO-d6 using an Agilent 400
series NMR instrument. The DMSO center line was set as
the reference at 2.5 ppm for 1H NMR spectra and at 39.51
ppm for 13 C NMR spectra. LRMS electron-impact (EI)
ionization mass spectra were recorded at 70 eV on a ThermoFinnigan PolarisQ (ion trap mass spectrometer). Samples
were introduced via a heatable direct probe inlet. Highresolution electron impact (EI) ionization mass spectra were
recorded at 25 eVon a JEOL JMS-700T MStation (magnetic
sector instrument) at a resolution of greater than 10,000.
Samples were introduced via heatable direct probe inlet.
MALDI mass spectra were obtained on a Bruker Utraflexstreme time-of-flight mass spectrometer (Billerica, Mass.),
using DHB (2,5-dihydroxybenzoic acid) matrix. Purity of
compounds was >95% as established by combustion analyses. In the case of compounds that resisted crystallization or
were too valuable to sacrifice to combustion, purity was
established by a combination of high-resolution mass spectra and 13 C NMR data. Elemental analyses were determined
by Atlantic Microlabs, Inc. (6180 Atlantic Blvd# M, Norcross, Ga., 30071, USA). Compounds were chromatographed on preparative layer Merck silica gel F254 or
colunms using MP Silica 63-200, 60 A, MP EcoChrom
(Eschwege, Germany). Organic solutions were dried over
anhydrous MgS04 unless otherwise noted.
Experimental Procedures and Characterization of Compounds 3A-8Aa:
General Procedure for the Synthesis of Ary! Bis[N(Guanidino )!mines] 3A-4H.
To a solution of aminoguanidine hydrochloride (2 mmol,
2 eq) in 3 mL of absolute EtOH at 78° C. was added 1 mmol
(1 eq) ofbisaldehyde 1 (R=H) or bisketone 2 (R=CH 3) and
10 µL of concentrated HCI. The mixture was heated for 2 h
and cooled to 0° C. The resulting white solid was filtered and
washed with 2 mL of cold EtOH to afford aryl N-(guanidino)
imines 3A-B and 4A,C-H as dihydrochloride salts.
Characterization of Compounds 3A-B and 4A,C-H:

°

1

15

CAS: 109501-35-1. Yield: 86%; mp 340-342° C. 1H
NMR (400 MHz, DMSO-d6) ll 7.84 (d, J=S.4 Hz, 4H, H-2),
7.85 (br s, SH, CH NNHC(N!__U N!b +), 7.98 (d, J=S.4
Hz, 4H, H-3), 8.24 (s, 2H, C!! NNHC(NH 2) NH 2+), 11.8
(br s, 2H, CH NNHC(NH2) NH2 +). 13 C NMR (100
MHz, DMSO-d6) Ii 127.0 (C-2), 128.2 (C-3), 133.0 (C-1),
140.9 (C-4), 146.3 ~H NNHC(NH 2) NH 2+), 155.4
(CH=NNH~(NH 2)=NH2+). HRMS (nEI) Calcd. for
C 16 H 21 Cl 2N 8 [M+Ht: 323.1727. Found: 323.1727. Anal.
Calcd. forC 16 H 20 Cl 2N 8 : C, 48.62; H, 5.10; N, 28.35. Found:
C, 48.72; H, 5.01; N, 28.20.
(2E,2'E)-2,2'-([ 1, 1'-Biphenyl]-3,4'-diylbis(methanylylidene) )bis(hydrazine-1-carboximidamide) dihydrochloride (38)

5'

20

NH2
9
2'

N....._N_,,,l.NH
H

•HCl

25

•HCl
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Yield: 73%; mp 368-370° C. 1H NMR (400 MHz,
DMSO-d6) ll 7.53 (t, J=S.O Hz, lH, H-5'), 7.78-7.85 (m, 4H,
H-2, H-4', H-6 and H-6'), 7.96 (d, J=S.4 Hz, 2H, H-3 and
H-5), 7.2-8.5 (br s, SH, CH NNHC(NH2) N!b +), 8.21 (s,
lH, CH NNHC(NH 2) NH 2+), 8.22 (br s, lH, H-2'), 8.23
(s, lH, CH NNHC(NH 2)=NH 2+), 12.1 (br s, 2H,
CH NNHC(NH2) NH2 +). 13 C NMR (100 MHz, DMSOd6) ll 125.6 (C-2'), 127.1 (C-2 and C-6), 127.2 (C-6'), 128.2
(C-3 andC-5), 128.8 (C-4'), 129.4 (C-5'), 132.9 (C-1'), 134.2
(C-1),
139.8
(C-3'),
141.2
(C-4),
146.4
~H=NNHC(NH 2)=NH 2+),
146.6
~H=NNHC(NH 2)=NH 2+),
155.4
(CH NNH
~(NH 2)=NH 2+),
155.5
(CH=NNH~(NH 2)=NH 2+).
HRMS (nEI) Calcd. for C 12H 19N 8 [M+Ht: 275.1727.
Found: 275.1726.
(2E,2'E)-2,2'-([1, 1'-Biphenyl]-4,4'-diylbis(ethan-1yl-1-ylidene) )bis(hydrazine-1-carboximidamide)
dihydrochloride 2 (4A)

45

50

(2E,2'E)-2,2'-([1, 1'-Biphenyl]-4,4'-diylbis(methanylylidene ))bis(hydrazine-1-carboximidamide) dihydrochloride1 (3A)
55

NH2
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CAS: 5961-64-8. Yield: 80%; mp >380° C. 1HNMR (400
DMSO-d 6)
Ii
2.4
(s,
6H,
C(C
MHz,
H3 ) NNHC(NH 2) NH 2+), 7.78 (d, J=S.4 Hz, 4H, H-2),
7.9 (br s, SH, C(CH 3)=NNHC(N!b)=NH2+), 8.07 (d,
J=S.4 Hz, 4H, H-3), 11.4 (br s, 2H, C(CH 3) NN
HCCNH2)=NH2+). 13 C NMR (100 MHz, DMSO-d6) ll 14.7
(C~H 3) NNHC(NH 2) NH 2+), 126.5 (C-2), 127.4 (C-3),
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136.2
(C-1),
140.3
(C-4),
151.2
~(CH 3) NNHC(NH 2) NH 2+), 156.1 (C(CH 3) NNH
QNH 2) NH 2+). HRMS (nEI) Calcd. for C 18 H 23 N 8
[M+Ht: 351.2040. Found: 351.2040. Anal. Calcd. for
C 18H 24Cl 2N 8: C, 51.07; H, 5.71; N, 26.47. Found: C, 51.15;
H, 5.68; N, 26.37.

(2E,2'E)-2,2'-((0xybis( 4, 1-phenylene))bis( ethan-lyl-1-ylidene ))bis(hydrazine-1 carboximidamide ),
dihydrochloride4 (4E)
5

(2E,2'E)-2,2'-( (methylenebis(4, 1-phenylene) )bis
(ethan- l-yl-1-ylidene ))bis(hydrazine-1-carboximidamide) dihydrochloride (4C)

15

NH2
'7'N'NANH
H
•HCl

Yield: 91%; mp 342-344° C. 1H NMR (400 MHz,
DMSO-d6) Ii 2.32 (s, 6H, C(C!_h)=NNHC(NH 2)=NH 2+),
4.02 (s, 2H, ArCH_2Ar), 7.28 (d, J=S.4 Hz, 4H, H-2), 7.81 (br
s, SH, C(CH 3) NNHC(N~)'N~ +), 7.87 (d, J=S.4 Hz, 4H,
H-3), 11.3 (br s, 2H, C(CH3) NNH_C(NH2) NH2 +). 13 C
NMR (100 MHz, DMSO-d 6) Ii 14.6 (C~H 3)=
NNHC(NH 2) NH 2+), 40.4 (~H 2Ar), 126.9 (C-2), 128.6
(C-3), 134.8 (C-1), 142.8 (C-4), 151.5 ~(CH 3)=
NNHC(NH 2) NH 2+),
156
(C(CH 3) NNH
QNH 2) NH 2+). HRMS (nEI) Calcd. for C 19 H 25 N 8
[M+Ht: 365.2197. Found: 365.2197. Anal. Calcd. for
C 19H 26 Cl 2N 8: C, 52.18; H, 5.99; N, 25.62. Found: C, 51.85;
H, 5.95; N, 25.31.
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CAS: 5265-92-9. Yield: 66%; mp >380° C. 1H NMR (400
Ii
2.33
(s,
6H,
C(C
MHz,
DMSO-d 6)
!b)=NNHC(NH2) NH 2+), 2.94 (s, 4H, Ar(C~) 2Ar),
7.25 (d, J=S.4 Hz, 4H, H-2); 7.81 (br s, SH, C(CH 3)
=NNHC(NH 2) NH 2+), 7.86 (d, J=S.4 Hz, 4H, H-3), 11.25
(br s, 2H, C(CH3)=NNH_C(NH2)=NH2+). 13 C NMR (100
MHz, DMSO-d 6) Ii 14.6 (C~H 3)=NNHC(NH 2)=NH 2+),
36.3 (Ar~H 2)2Ar), 126.7 (C-2), 128.4 (C-3), 134.5 (C-1),
143.1 (C-4), 151.6 ~(CH 3) NNHC(NH 2) NH 2+), 156.0
(C(CH 3) NNHQNH 2) NH 2+). HRMS (nEI) Calcd. for
C 20 H 27N 8 [M+Ht: 379.2352. Found: 379.2352. Anal.
Calcd. forC 20 H 28 Cl 2N 8: C, 53.22; H, 6.25; N, 24.82. Found:
C, 52.93; H, 6.09; N. 25.05.

(2E,2'E)-2,2'-((9H-Fluorene-2, 7-diyl)bis(ethan-1-yll-ylidene ))bis(hydrazine-1-carboximidamide) dihydrochloride (4F)

30

(2E,2'E)-2,2'-( (Ethane-1,2-diylbis(4, 1-phenylene))
bis(ethan- l-yl-1-ylidene ))bis(hydrazine-1-carboximidamide) dihydrochloride3 (4D)

•HCl

CAS: 17027-93-9. Yield: 73%; mp 340-342° C. 1H NMR
(400 MHz, DMSO-d 6) Ii 2.35 (s, 6H, C(C
H_3) NNHC(NH 2) NH 2-), 7.08 (d, J=S.4 Hz, 4H, H-2),
7.74 (br s, SH, C(CH 3) NNHC(NH_2) NH_2+), 8.02 (d,
J=S.4 Hz, 4H, H-3), 11.0 (br s, 2H, C(CH 3) NN
H_C(NH 2)=NH 2+). 13 C NMR (100 MHz, DMSO-d 6) ll 14.6
(C(CH_3) NNHC(NH 2) NH 2+), 118.3 (C-2), 128.8 (C-3),
132.4 (C-4), 150.9 ~(CH 3) NNHC(NH 2) NH 2+), 156
(C-1), 157.5 (C(CH 3)=NNH~(NH 2)=NH 2+). HRMS
(nEI) Calcd. for C 18H 23 Ng0 [M+Ht: 367.1989. Found:
367.1987. Anal. Calcd. for C 18 H 24 Cl 2N 80: C, 49.21; H,
5.51; N, 25.51. Found: C, 49.12; H, 5.53; N, 25.43.

50

55

CAS: 63956-03-6, NCI 304392. Yield: 96%; mp >380° C.
1H NMR (400 MHz, DMSO-d ) Ii 2.42 (s, 6H, C(CH )
3
6
NNHC(NH 2) NH 2+), 4.01 (s, 2H, H-7), 7.88 (br s, SH,
C(CH 3)=NNHC(NH 2)=NH 2+), 8.01 (d, J=S.4 Hz, 2H,
H-4), 8.03 (d, J=S.4 Hz, 2H, H-3), 8.24 (s, 2H, H-1), 11.33
(br s, 2H, C(CH 3)=NNHC(NH 2)=NH 2+). 13 C NMR (100
MHz, DMSO-d6) ll 14.8 (C~H 3)=NNHC(NH 2)=NH 2+),
36.5 (C-9), 120.3 (C-4), 123.6 (C-1), 125.9 (C-3), 135.8
(C-6), 141.9 (C-5), 143.8 (C-2), 151.8 (C(CH 3) NNHC
(NH 2)=NH 2+), 156.1 (C(CH 3)=NNHC(NH 2)=NH 2+).
HRMS (nEI) Calcd. for C 19H 23 N 8 [M+Ht: 363.2040.
Found: 363.2039. Anal. Calcd. for C 19H 24 Cl 2N 8.1hH 20: C,
51.36; H, 5.67; N, 25.22. Found: C, 51.19; H, 5.59; N, 25.06.
(2E,2'E)-2,2'-(1,4-Phenylenebis(ethan-1-yl-1ylidene) )bis(hydrazine-1-carboximidamide) dihydrochloride4 (4G)

•HCl
H
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~N/NYNH
NH2
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CAS: 2299-94-7. Yield: 97%; mp>380° C. 1H NMR (400
Ii
2.38
(s,
6H,
C(C
MHz,
DMSO-d 6 )
!b)=NNHC(NH2+) NH 2+), 7.87 (br s, SH, C(CH 3)
=NNHC(NH_2) N~ -), 7.99 (s, 4H, H-2, H-3), 11.3 (br s,
2H, C(CH3) NNH_C(NH2) NH2 +). 13 C NMR (100 MHz,
DMSO-d6 ) Ii 14.7 (ArC( NNHR)~H 3), 126.6 (C-2, C-3,
C-5, and C-6), 137.8 (C-1 and C-4), 151.1 (Ar
Q NNHR)CH 3), 156.067 (NH~(NH 2)=NH 2+). HRMS
(nEI) Calcd. for C 12 H 19N 8 [M+Ht: 275.1727. Found:
275.1726. Anal. Calcd. for C 12H 20 Cl 2N 8 . 1/2H 20: C, 40.46;
H, 5.94; N, 31.45. Found: C, 40.68; H, 6.10; N, 31.26.

Characterization of Compounds 7Aa-Ag and 8Aa:

5

E)-2-(( 4'-((E and Z)-(2-(2-Chlorophenyl)hydrazono)
methyl)-[ 1, 1'-biphenyl]-4-yl)methylene)hydrazine-1carboximidamide monohydrochloride (7 Aa)

3'

10

:::::,_,...ND,,~"°"
H

Cl

(2E,2'E)-2,2'-(1,3-Phenylenebis( ethan-1-yl-1ylidene))bis(hydrazine-1-carboximidamide) dihydrochloride 6 (411)
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General Procedure for the Synthesis of Ary! N-(Guanidino )!mines N'-Arylhydrazones 7Aa-Ag and 8Aa.
To 40.5 mmol (3 eq) of a bis(aldehyde) IA (R=H) or
bis(ketone) 2A (R=CH 3) in 20 mL of absolute EtOH at 78°
C. was added dropwise a solution of 1.5 g (13.5 mmol, 1 eq)
of aminoguanidine hydrochloride in 80 mL of 1:15/H20:
EtOH. To this solution was added 2 mL of concentrated HCI,
and the mixture was heated for an additional 12 h. The
mixture was concentrated under vacuum to afford a solid.
The solid was heated with ca. 10 mL of EtOAc to dissolve
any unreacted dicarbonyl compound, as confirmed by TLC
of the undissolved solid using 1:50/MeOH:CH2Cl 2. After
decanting the EtOAc solution, the remaining white precipitate consisted of the mono substituted N-(guanidino )imine
SA and 6A that was used directly in the next step. To 113 mg
(0.5 mmol, 1 eq) of SA or 6A suspended in 2 mL of absolute
EtOH at 78° C. was added 0.5 mmol (1 eq) of an aryl
hydrazine followed by 0.02 mL of concentrated HCI. A clear
solution was produced by the addition of acid, and within
15-30 min, a precipitate was formed. The mixture was
heated at 78° C. for 24 h, and the precipitate was collected
by filtration of the hot mixture. The precipitate was washed
cold absolute EtOH to yield >95% of pure unsymmetrical
aryl N-(guanidino)imines N'-arylhydrazones 7Aa-Ag and
8Aa.

2'1

5"

#4"
3

,,

15
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CAS: 87533-31-1. Yield: 86%; mp 330-332° C. 1H NMR
Ii 2.42 (s, 6H, C(C
(400 MHz, DMSO-d 6 )
!b)=NNHC(NH2) NH 2+), 7.47 (t, 1=8.0 Hz, lH, H-5),
7.87 (br s, SH, C(CH 3)=NNHC(N~)=NH_2+), 8.03 (dd,
1=8.0 and 2.0 Hz, 2H, H-4 and H-6), 8.26 (t, 1=2.0 Hz, lH,
H-2), 11.34 (br s, 2H, C(CH3)=NNHCCNH2) NH2 +). 13 C
NMR (100 MHz, DMSO-d 6 ) Ii 15.0 (CH 3), 124.8 (C-5),
128.0 (C-4 and C-6), 128.4 (C-2), 137.1 (C-1 and C-3),
151.7 QCH3)=NNHC(NH 2)=NH 2+), 156.2 (C(CH 3)
=NNH~(NH 2) NH 2+). HRMS (nEI) Calcd. for C 12 H 19 N 8
[M+Ht: 257.1727. Found: 275.1726. Anal. Calcd. for
C 12H 20 Cl 2N 8 : C, 41.51; H, 5.81; N, 32.27. Found: C, 41.27;
H, 5.71; N, 32.13.

6"

N

45

Yield: 70%; mp 328-330° C. 1H NMR, (400 MHz,
DMSO-d6 ) ll 6.81 (dt, 1=8.4 and 1.6 Hz, lH, H-4"), 7.28 (dt,
1=7.6 and 1.2 Hz, lH, H-5"), 7.34 (dd, 1=8.0 and 1.6 Hz, 1,
H-3"), 7.6 (dd, 1=8.4 and 1.2 Hz, lH, H-6"), 7.75-7.80 (m,
4H, H-2 and H-2'), 7.80 and 7.84 (two d, 1=8.4 Hz, lH,
45:55 ratio ofsyn:anti H-3'), 7.97 and 7.98 (two d, 1=8.4 Hz,
lH, 45:55 ratio of syn:anti H-3), 8.23 and 8.234 (twos, lH,
45:55 ratio of syn:anti ~H NNHAr), 8.34 (s, lH,
~H NNHC(NH 2) NH 2+), 9.98 and 10 (two br s, lH,
55:45 ratio of anti:syn CH=NNH_Ar), 12.03 and 12.08 (two
br s,
lH, 45:55 ratio of syn:anti CH NN
H_C(NH 2)=NH 2+). 13 C NMR (100 MHz, DMSO-d 6 ) Ii
114.1 (C-2"), 116.23 and 116.3 (anti:syn C-6"), 119.7 and
119.8 (anti:syn C-4"), 126.6 and 126.8 (anti:syn C-2'), 126.6
and 126.8 (anti:syn C-3'), 126.7 and 126.8 (syn:anti C-2),
127 and 127.1 (anti:syn C-3), 128.1 and 128.3 (syn:anti
C-3'), 129.4 (C-3"), 132.7 and 133 (syn:anti C-1 '), 134.7 and
135.1 (anti:syn C-1), 139.1 and 139.4 (anti:syn C-4'), 139.8
and 139.9 (syn:anti C-4'), 140.9 and 141.3 (syn:anti C-1'),
141.33 and 141.3 (syn:anti ~H=NNHC(NH 2)=NH 2+),
146.3 and 146.4 (anti:syn ~H=NNHAr), 155.38 and 155.4
(syn:anti CH=NNHQNH 2) NH 2+). HRMS (nEI) Calcd.
forC 21 H 20N 6 Cl [M+Ht: 391.1432. Found: 391.1431.Anal.
Calcd. forC 21 H 20 C 12 N 6 . 1hH 20: C, 57.81; H, 4.85; N, 19.26.
Found: C, 58.46; H, 4.69; N, 19.27.
(E)-2-((4'-((E and Z)-(2-(2-Bromophenyl)hydrazono )methyl)-[!, 1'-biphenyl]-4-yl)methylene)hydrazine-1-carboximidamide monohydrochloride (7Ab)
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Yield: 64%; mp >380° C. 1H NMR (400 MHz, DMSO-d 6 )
Ii 6.75 (dt, 1=8.4 and 1.6 Hz, lH, H-4"), 7.32 (dt, 1=7.6 and
1.2 Hz, lH, H-5"), 7.5 (dd, 1=8.0 and 1.6 Hz, lH, H-3"), 7.58
(dd, 1=8.4 and 1.2 Hz, lH, H-6"), 7.75-7.85 (m, 6H, H-2,
H-2', and H-3'), 7.80 (br s, 4H, CH=NNHC(N~)=NH 2+),
7.97 and 7.98 (two d, 1=8.4 Hz, lH, 45:55 ratio of syn:anti
H-3), 8.227 and 8.232 (two s, lH, 45:55 ratio of syn:anti C
H NNHAr), 8.364 (s, lH, CH=NNH_C(NH2)=NH2+),
9.74 and 9.75 (two br s, lH, 45:55 ratio ofanti:syn CH NN
H_Ar), 11.97 and 12.03 (two br s, lH, 45:55 ratio of syn:anti
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CH NNHC(NH 2) NH 2+). 13 C NMR (100 MHz, DMSOd6) Ii 106.1 and 106.2 (anti:syn C-2"), 114.6 (C-6"), 120.4
and 120.5 (anti:syn C-4"), 126.66 and 126 72 (anti:syn C-2),
126.7 and 127 (anti:syn C-3'), 126.8 and 127.1 (anti:syn
C-2'), 128.3 (C-3), 128.6 (C-5"), 132.6 (C-1'), 132.6 and 133
(anti:syn C-3"), 134.7 and 135.1 (anti:syn C-1), 139.1 and
139.4 (anti:syn C-4"), 140 and 140.1 (syn:anti C-4), 141 and
141.3 (anti:syn C-1"), 142.34 and 142.38 (syn:anti
~H NNHC(NH 2) NH 2+), 146.4 and 146.5 (syn:anti
~H NNHAr), 155.34 and 155.36 (syn:anti CH NNH
QNH 2) NH 2+). HRMS (nEI) Calcd. for C 21 H 19BrN6
[M+Ht: 435.0927. Found: 435.0928. Anal. Calcd. for
C 21 H 20 BrClN6: C, 53.46; H, 4.27; N, 17.81. Found: C,
53.10; H, 4.29; N, 17.19.

30

5

10

12.05 (br s, lH, CH=NNHCCNH2)=NH2+). 13 C NMR
(100 MHz, DMSO-d 6) Ii 113.5 (C-2"), 122.0 (C-4"), 126.3
(C-2'), 126.7 (C-2), 127 (C-3'), 128.2 (C-3), 128.9 (C-3"),
133 (C-1'), 134.8 (C-1), 136.8 ~H NNHAr), 139.0 (C-4'),
~H=
141.0
(C-4),
144.2
(C-1"),
146.4
NNHC(NH 2)=NH 2-), 155.4 (CH=NNH~(NH 2)=NH 2+).
HRMS (nEI) Calcd. for C21 H 20 ClN 6 [M+Ht: 391.1432.
Found: 391.1431. Anal. Calcd. for C 21 H 20 Cl 2N 6: C, 59.02;
H, 4.72; N, 19.67. Found: C, 59.22, H, 4.75; N, 19.46.
(E)-2-((4'-((E and Z)-(2-( 4-Cyanophenyl)hydrazono)
methyl)-[ 1, 1'-biphenyl]-4-yl)methylene)hydrazine-1carboximidamide monohydrochloride (7 Ae)

15

(E)-2-((4'-((E)-(2-( 4-Fluorophenyl)hydrazono)
methy1)-[ 1, 1'-biphenyl ]-4-yl)methy lene)hydrazine-1carboximidamide monohydrochloride (7 Ac)
20
NH2
3'
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Yield: 88%; mp >380° C. 1HNMR(400MHz, DMSO-d6)
ll 7.07 (d, J=7.6 Hz, 2H, H-2"), 7.09 (d, J=7.6 Hz, 2H, H-3"),
7.73 (s, 4H, H-2 and H-2'), 7.82 (br s, 4H, CH=NNHC(N
~)=N!:!2+), 7.84 (d, J=8.4 Hz, 2H, H-3'), 7.91 (s, lH, C
!:! NNHAr), 7.98 (d, J=8.4 Hz, 2H, H-3), 8.24 (s, lH, C
!:! NNHC(NH 2) NH 2+), 10.5 (br s, lH, CH=NN!:!Ar),
12.08 (br s, lH, CH=NNHCCNH2)=NH2+). 13 C NMR
(100 MHz, DMSO-d 6) Ii 113 (C-2"), 115.6 (C-3"), 126.2
(C-2'), 126.6 (C-2), 127.0 (C-3'), 128.2 (C-3), 133.0 (C-1'),
135 (C-1), 136 ~H NNHAr), 138.8 (C-4'), 140.9 (C-4),
141.9 (C-1"), 146.3 ~H NNHC(NH 2)=NH 2+), 155.4
(CH NNH~(NH 2)=NH 2+), 156.4 (C-4"). HRMS (nEI)
Calcd. forC 21 H 20 FN 6 [M+Ht: 375.1728. Found: 375.1728.
Anal. Calcd. for C 21 H 20 ClFN 6: C, 61.39; H, 4.94; N, 20.18.
Found: C, 61.48; H, 4.94; N, 20.18.
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(E)-2-((4'-((E)-(2-( 4-Chlorophenyl)hydrazono)
methy1)-[ 1, 1'-biphenyl ]-4-yl)methy lene)hydrazine-1carboximidamide monohydrochloride (7 Ad)

Yield: 33%; mp 308-310° C. 1H NMR (400 MHz,
DMSO-d6) Ii 7.19 (d, J=8.4 Hz, 2H, H-2"), 7.64 (d, J=8.4
Hz, 2H, H-3"), 7.4-7.8 (br s, 4H, CH NNHC(NH.2) N
!:!2+), 7.76-7.85 (m, 6H, H-2, H-2', and H-3'); 7.973 and
7.981 (two d, J=8.0 Hz, 2H, 58:42 ratio of anti:syn H-3),
8.036 and 8.041 (two s, lH, 58:42 ratio of anti:syn C
H NNHAr), 8.220 and 8.226 (two s, lH, 58:42 ratio of
anti:syn CH NNHC(NH 2) NH 2+), 11.12 and 11.16 (two
br s, lH, 58:42 ratio of anti:syn CH NNHAr), 11.87 and
11.93 (two br s, lH, 58:42 ratio of anti:syn CH NN
HCCNH2)=NH2 +). 13 C NMR (100 MHz, DMSO-d6) Ii
99.35 (syn Ar~N), 99.40 (anti Ar~N), 112.2 (C-2"),
120.1 (C-4"), 126.74 (anti C-2), 126.82 (syn C-2'), 126.819
(anti C-3'), 126.98 (syn C-3'), 132.69 (anti C-1 '), 132.98 (syn
C-1'), 133.7 (C-3"), 134.4 (syn C-1), 134.7 (anti C-1), 139.3
and 139.5 (syn:anti ~H NNHAr), 139.57 and 139.60 (anti:
syn C-4'), 140.96 and 141.2 (syn:anti C-4), 146.4 and 146.5
(syn:anti ~H=NNHC(NH 2)=NH 2+), 148.54 (anti C-1"),
148.55 (syn C-1 "), 155.26 and 155.3 (anti:syn CH NNH
~(NH 2)=NH 2+). HRMS (nEI) Calcd. for C 22 H 19ClN7
[M+Ht: 382.1775. Found: 382.1771. Anal. Calcd. for
C 22 H 20 ClN7 : C, 63.23; H, 4.82; N, 23.46. Found: C, 63.17;
H, 4.80; N, 23.16.

50

(E)-2-(( 4'-((E)-(2-(2,4-Difluorophenyl)hydrazono)
methyl)-[1,1 '-biphenyl]-4-yl)methylene) hydrazine1-carboximidamide, monohydrochloride (7 Af)
55

60

Yield: 80%; mp >380° C. 1HNMR(400MHz, DMSO-d6)
ll 7.10 (d, J=8.4 Hz, 2H, H-2"), 7.26 (d, J=8.4 Hz, 2H, H-3"),
7.74 (brs, 4H, CH=NNHC(N~)=N!:!2+), 7.74 (s, 4H, H-2
and H-2'), 7.84 (d, J=8.4 Hz, 2H, H-3'), 7.93 (s, lH, C
!:! NNHAr), 7.98 (d, J=8.4 Hz, 2H, H-3), 8.23 (s, lH, C
!:! NNHC(NH 2) NH 2+), 10.65 (br s, lH, CH=NN!:!Ar),

NH2

HNAN,..N~
•HCl
65

H

Yield: 84%; mp >380° C. 1H NMR (400 MHz, DMSO-d 6)
Ii 7.02 (dt, J=9.6 and 2.8 Hz, lH, (H-3"), 7.22 (ddd, J=ll.6,
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8.4, and 2.8 Hz, lH, H-6"), 7.53 (dd, J=9.6 and 6.0 Hz, lH,
H-5"), 7.74 (br s, 4H, CH NNHC(NH_2) NH_2+), 7.75 (s,
4H, H-2 and H-2'), 7.85 (d, J=8.4 Hz, 2H, H-3') 7.98 (d,
J=8.4
Hz,
2H,
H-3),
8.15
(s,
lH,
C
H=NNHC(NH 2) NH 2+), 8.22 (s, lH, CH_ NNHAr),
10.29 (br s, lH, CH=NNH_Ar), 11.8 (br s, lH, CH NN
HC(NH 2) NH 2-). 13 C NMR (100 MHz, DMSO-d 6) Ii
104.0 (C-6"), 111.5 (C-3"), 114.1 (C-5"), 126.5 (C-2'), 126.7
(C-2), 126.1 (C-3'), 128.3 (C-3), 130.3 (C-1"), 133.0 (C-1'),
134.8 (C-1), 139.0 (C-4'),
139.2 (C-4),
141.0
~H NNHAr), 146.3 ~H NNHC(NH 2) NH 2+), 153.1
(C-4"), 155.6 (C-2"), 155.4 (CH NNH~(NH 2)=NH 2+).
HRMS (nEI) Calcd. for C 21 H 19 N 6F 2 [M+Ht: 393.1634.
Found: 393.1631.Anal. Calcd. forC 21 H 19N 6ClF 2: C, 58.81;
H, 4.47; N, 19.60. Found: C, 58.37; H, 4.41; N, 19.44.

Yield: 95%; mp >380° C. 1 HNMR (400MHz, DMSO-d6)
Ii 2.36 (s, 3H, C(CH_3 ) N-NH-Ar), 2.37 (s, 3H, C(C
H 3 ) N-NH----C(NH 2) NH 2+), 6.87 (dt, J=8.0 and 1.2
Hz, lH, H-4"), 7.32 (dt, J=8.0 and 1.2 Hz, lH, H-5"), 7.39
(dd, J=8.0 and 1.2 Hz, lH, H-6"), 7.65 (dd, J=8.0 and 1.2 Hz,
lH, H-3"), 7.20-8.20 (br s, 4H, C(CH 3 )=N-NH-C(N
H 2) N~ +), 7.78 (d, J=8.4 Hz, 2H, H-2' and H-6'), 7.79 (d,
J=8.4 Hz, 2H, H-3' and 5'), 7.95 (d, J=8.4 Hz, 2H, H-2 and
H-6), 8.08 (d, '=8.4 Hz, 2H, H-3 and H-5), 8.28 (s, lH,
C(CH 3 )=N-NH_-Ar), 10.83 (br s, lH, C(CH 3 )=N-N
H----C(NH 2) NH 2+). 13 C NMR (100 MHz, DMSO-d 6) Ii
12.5
C~H 3 )=N-NH-Ar),
13.8
(C(
CH 3 ) N-NH----C(NH 2) NH 2+), 114.7 (C-2"), 117.5
(C-6"), 120.3 (C-4"), 126.2 (C-2'), 126.47 (C-3'), 126.5
(C-1 ), 127.4 (C-5"), 128.2 (C-3), 133.6 (C-1 '), 137 .7
(C-3"), 139.2 (C-4'), 140.3 (C-4), 141.4 (C-1"),
147.8
~(CH 3 ) N-NH-Ar),
151.4
~(CH 3 )=
NNHC(NH 2)=NH 2+),
155.7
(C(CH 3 ) NNH
~(NH 2)=NH 2+). Anal. Calcd. for C 23 H 24Cl 2N 6: C, 60.66;
H, 5.31; N, 18.46. Found: C, 60.43; H, 5.28; N, 18.52.
Bacterial and Fungal Strains.
The bacterial strains B. subtilis 168 (strain A) was
obtained from the Bacillus Genetic Stock Center (Ohio State
University). L. monocytogenes ATCC 19115 (strain B), A.
baumannii ATCC 19606 (strain E), E. coli MC1061 (strain
G), K. pneumoniae ATCC 27736 (strain H), and S. enterica
ATCC 14028 (strain J) were gifts from Dr. Paul Hergentorther (University of Illinois Champagne-Urbana). MRSA
(strain C) and VRE (strain D) were obtained from Dr. David
Sherman (University of Michigan). The E. cloacae ATCC
13047 (strain F) and P. aeruginosa ATCC 27853 (strain I)
were gifts of Dr. Dev P. Arya (Clemson University). M.
smegmatis MC2-155 (strain K) was obtained from Dr.
Sabine Erht (Cornell University). The yeast strains Candida
albicans ATCC 10231, C. albicans ATCC 64124, and C.
albicans ATCC MYA-2876 were gifts from Dr. Jon Y.
Takemoto (Utah State University, Logan, Utah, USA). The
yeast strains C. albicans ATCC MYA-90819, C. albicans
ATCC MYA-2310, C. albicans ATCC MYA-1237, and C.
albicans ATCC MYA-1003 were obtained from the American Type Culture Collection (ATCC; Manassas, Va., USA).
Determination of MIC Values for Compounds 3A-B,
4A,C-H, 7Aa-Ag, and 8Aa as Antibacterials.
MIC values were determined against a variety of Grampositive (strains A-D) and Gram-negative (E-J) bacterial and
mycobacterial (K) strains using the double-dilution method,
as previously published. Preliminary screening was performed using 500 µM of each compound. Compounds that
were found to inhibit the growth of bacteria at 500 µM were
then tested in a range of 0.5 to 250 µM, and bacteria were
grown at 37° C. in Mueller-Hinton (MH) broth.
Development of Bacterial Resistance.
The development of resistance of L. monocytogenes
ATCC 19115 (strain B), MRSA (strain C), VRE (strain D),
and P. aeruginosa ATCC 27853 (strain I) to compounds 4D,
4F and 7Aa as well as AMK as a reference was determined
b/ following a previously published protocol. The ~acteria
were grown in MH broth at 37° C. for these expenments.
Briefly, the lh MIC concentration, from an active MIC
experiments, was diluted 1: 100 and grown overnight at 37°
C. The resulting cultures were diluted 1: 1000 and grown
until the culture reached -300,000 cfu/mL. That culture was
then further diluted 1: 1000 and used to determine the next
round of MIC values. MIC values were determined every
other day for a total of 15 rounds (Note: for the bacterial
strains that developed resistance to compounds prior to the
15 passages, the MIC value determination was discontinued
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(E)-2-(( 4'-((E)-(2-(2,4-dichlorophenyl)hydraz?no)
methy1)-[ 1, 1'-biphenyl ]-4-yl)methy lene)hydrazme-1carboximidamide hydrochloride (7 Ag)
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Yield: 80%; mp 356-358° C. 1 H NMR (400 MHz,
DMSO-d6) Ii 7.33 (d, J=8.8 and 2.4 Hz, lH, H-5"), 7.48 (d,
J=2.4 Hz, lH, H-3"), 7.59 (d, J=8.8 Hz, lH, H-6"), 7.5-8.2
(br s, 4H, C=HN-NH-C(NH_2) N~ +), 7.77 (s, 4H,
H-2', H-3', H-5', and H-6'), 7.84 (d, J=8.4 Hz, 2H, H-2 and
H-6), 7.98 (d, J=8.4 Hz, 2H, H-3 and H-5), 8.22 (s, lH,
H-CH=N-NH-Ar),
8.35
(s,
lH,
C
H=N- NH----C(NH 2) NH 2+), 10.12 (s, lH, CH=N-N
H-Ar), 11.78 (s, lH, CH N-NH_-C(NH 2)=NH2+).
De NMR (100 MHz, DMSO-d6) Ii 116.7 C-6"), 122.3
(C-4"), 126.1 (C-2"), 126.75 (C-2), 126.85 (C-2'), 126.97
(C-3'), 128.1 (C-3), 128.6 (C-3"), 129.4 (C-5"), 133.0 (C-1'),
134.5
(C-1),
139.6
(C-4'),
140.5
(C-1 "),
140.6
~H=NNHAr),
140.7
(C-4),
146.5
~H NNHC(NH 2)=NH 2+),
155.2
(CH NNH
QNH 2) NH 2+). The observed CHN combustion analysis
data (Found: C, 54.96; H, 4.04; N, 17.52 and C, 54.79; H,
4.19; N, 17.58) did not match pure 7Ag (Calcd: C, 56.40; H,
4.73; N, 17.16) but was consistent with 3.1% of (2E,2'E)2,2'-([1, 1'-biphenyl]-4,4'-diylbis(methanylylidene))-bis(hydrazine-1-carboximidamide) dihydrochloride 1 (3A).
(E)-2-(1-(4'-( (E)-1-(2-(2-chlorophenyl)hydrazono)
ethyl)-[1, 1'-biphenyl]-4-yl)ethylidene)hydrazine-1carboximidamide hydrochloride (8Aa)
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post resistance observation). The fold changes of the MIC
values were determined and these data are presented in FIG.
2.
Determination of MIC Values for Compounds 3A-B,
4A,C-H, 7Aa-Ag, and 8Aa as Antifungals.
In vitro MIC testing was performed according to the CLSI
M27-A3 standard microbroth dilution methodology for the
susceptibility testing of yeasts with minor modifications.
Briefly, serial dilutions of the test compounds as well as a
reference compound, AmB, were prepared in RPMI 1640
medium (catalog# R6504, Sigma-Aldrich Chemical Co., St.
Louis, Mo.) buffered to pH 7 with 0.165 M morpholinepropanesulfonic acid (MOPS) buffer (Sigma-Aldrich Chemical
Co.) using 96-well plates in a range of0.48-31.2 µg/mL, and
microtiter plates were then incubated at 35° C. for 2 days.
MIC values were read visually for all tested compounds, and
the endpoint was determined as the minimum concentration
of compound that yielded complete inhibition relative to
growth control.
Development of Fungal Resistance.
C. albicans ATCC 10231 was used to perform the development of resistance of this strain to compounds 4F and
7Aa, as well as AmB as a reference. Firstly, MIC values of
4F, 7Aa, and POS against this strain were determined in
96-well plates using RPMI 1640 medium at 35° C. for 48 h.
Aliquot of 10 µL from the well that was showing the 1h MIC
values were subcultured into PDA and grown overnight at
35° C. A single colony was picked to inoculate fresh RPMI
1640 medium and that culture was used to determine the
next round of MIC values. The MIC values for each compound were determined every third day for a total of 15
passages of MIC determination. The fold changes of the
MIC values were determined and these data are presented in
FIG. 2.
Assays for Reactive Oxygen Species (ROS) Production.
We used the 2',7'-dichlorodihydrofluorescein diacetate
(DCFH-DA) dye as a probe to measure the production of
ROS in yeast cells upon treatment with our compounds.
DCFH-DA can easily cross the cell membranes and be
hydrolyzed by cellular esterases to the non-fluorescent 2',7'dichlorodihydrofluorescein (DCFH), which can further be
oxidized to the highly fluorescent 2',7'-dichlorofluorescein
(DCF) by the intracellular ROS. Five mL of RPMI 1640
medium were inoculated using a single colony of C. albicans ATCC 10231 (strain A) in a Falcon tube and grown
overnight at 35° C. at 200 rpm. The overnight culture was
diluted by adding 200 µL of yeast cells to 800 µL of the same
medium. Cell suspension (100 µL) was added to the RPMI
1640 medium containing no drug (negative control) or
compounds 4F and 7Aa at their lx and 2x MIC values, and
treated for 1 h at 35° C. H 2 0 2 at 1 mM was also used as a
positive control. Cells were centrifuged and washed twice
with PBS buffer (pH 7.2). Cells were resuspended in the
same buffer and incubated with DCFH-DA (20 µg/mL) for
30 min in the dark. Afterwards, cells were centrifuged and
washed with PBS buffer to remove excess DCFH-DA. Glass
slides with 10-15 µL of each mixture were prepared and
observed in bright field and fluorescence modes (FITC filter
set, excitation and emission wavelengths of 488 and 512 nm,
respectively) using a Zeiss Axovert 200M fluorescence
microscope (FIG. 3).
Toxicity Studies.
Cytotoxicity assays were performed as previously
described. The human lung carcinoma epithelial cells A549
and the normal human bronchial epithelial cells BEAS-2B
were grown in Fl2-K and DMEM medium containing 10%
fetal bovine serum (FBS) and 1% antibiotics, respectively.

The confluent cells were trypsinized with 0.05%-trypsin0.53 mM EDTA, centrifuged (1,200 rpm) and resuspended
in fresh medium (Fl2-K or DMEM). The cells were seeded
into 96-well microtiter plates at a density of 3,000 cells/well
and were grown overnight. The following day, the media
were replaced by 100 µL of fresh culture media containing
serially diluted compounds 3A-B, 4A,C-H, and 7Aa-Af, as
well as a reference compound, AmB, (at final concentrations
of0.24-31.2 µg/mL or sterile ddH 2 0 (negative control). The
cells were incubated for an additional 24 hat 37° C. with 5%
C0 2 in a humidified incubator. Each well was treated with
10 µL (25 µg/mL) ofresazurin sodium salt (Sigma-Aldrich)
for 3-6 h to determine cell viability. Metabolically active
cells can convert the blue non-fluorescent dye resazurin to
the pink and highly fluorescent dye resorufin, which can be
detected at A 560 excitation and A 590 emission wavelengths
by using a SpectraMax MS plate reader. Triton X-100®
(0.5%, v/v) gave complete loss of cell viability and was used
as the positive control. The percent cell survival was calculated as: (test value/control value )xl 00, where control value
represents cells+resazurin-drug, and test value represents
cells+resazurin+drug. These data are presented in FIGS.
4A-B.
Cell-Based [3 H]Dofetilide Binding Assay.
HEK-293 cell membranes which specifically and stably
express the hERG channel protein were prepared and harvested as previously described. Assays were conducted in
duplicate, and three independent assays were performed for
each compound that was evaluated. Cell membrane suspension (5 µg) was added to duplicate tubes containing assay
buffer (50 mM Tris, 10 mM KC!, and 1 mM MgCl 2 , pH 7.4),
25 µL of a single concentration of analogue (a concentration
range of 10 nM-100 µM was employed for each experiment), and 25 µL of [3 H]dofetilide (5 nM, final concentration) for an assay volume of 250 µL. Nonspecific binding
was assessed in the presence of 1 mM amitriptyline. Binding
occurred for 60 min at 25° C. and was terminated by rapid
filtration through Whatman GF/B filters, which were presoaked in 0.5% PEI for 2 h. Filters were washed three times
with -1 mL of ice-cold assay buffer. Radioactivity retained
by the filters was determined by liquid scintillation counting
by using a Tri-Carb 2100TR liquid scintillation analyzer
(PerkinElmer Life and Analytical Sciences, Boston, Mass.).
These data are presented in FIG. 5.
In summary, amidinohydrazone compounds such as nine
bis(N-amidino )hydrazones and eight N-amidino-N'-arylbishydrazones were shown to have antifungal activity and
their activity was not readily predicable from their antibacterial activity. In addition, the amidinohydrazone compounds displayed low potential for resistance development,
and were found to induce ROS production in a C. albicans
strain. They were also found to display reasonable toxicity
profiles against two mammalian cell lines as well as only
moderate, acceptable hERG channel inhibition. In light of
our SAR study, compounds 4F, 7Ac, and 7Af, were preferred embodiments of the disclosure.
Only the preferred embodiment of the present invention
and examples of its versatility are shown and described in
the present disclosure. It is to be understood that the present
invention is capable of use in various other combinations
and environments and is capable of changes or modifications
within the scope of the inventive concept as expressed
herein. Thus, for example, those skilled in the art will
recognize, or be able to ascertain, using no more than routine
experimentation, numerous equivalents to the specific substances, procedures and arrangements described herein.
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Such equivalents are considered to be within the scope of
this invention, and are covered by the following claims.
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3. The method of claim 1, wherein the compound 1s
according to formula (IV):

What is claimed is:
1. A method for treating a fungal infection, the method
comprising administering to a subject in need thereof a
therapeutically effective amount of a compound according to
formula (I):

R
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35

N-NH

or a pharmaceutically acceptable salt thereof, wherein
each R is independently H or a lower alkyl, wherein
each R 1 is independently an amidino or a phenyl, and
wherein the linker is

40

45
or

( ) ( )

.

2. The method of claim 1, wherein the compound is
according to formula (III):

55

(III)

or a pharmaceutically acceptable salt thereof; wherein
each R2 is independently selected from the group
consisting of H, a lower alkyl, a phenyl, a substituted
lower alkyl, or a substituted phenyl.

(IV)

or a pharmaceutically acceptable salt thereof; wherein Ar
is a phenyl group; wherein each X is independently
selected from the group consisting of an electronwithdrawing group selected from the group consisting
of a halogen, a carbonyl group, sulfoxide, sulfone,
sulfonate, sulfonamide, a nitro group, a cyano group;
and wherein each n is independently between O and 5,
with O representing an unsubstituted phenyl group.
4. The method of claim 3, wherein each X is independently selected from the group consisting of fluorine, chlorine, and bromine.
5. The method of claim 1, wherein the compound is
according to formula (V):

(V)
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(I)

R

R\ }-linker--{ l
HN-N

5

65

or a pharmaceutically acceptable salt thereof; wherein Ar
is a phenyl group; wherein each X is independently
selected from the group consisting of an electronwithdrawing group selected from the group consisting
of a halogen, a carbonyl group, sulfoxide, sulfone,
sulfonate, sulfonamide, a nitro group, a cyano group;
wherein n is between O and 5, with O representing an
unsubstituted phenyl group; and wherein R2 is selected
from the group consisting ofH, a lower alkyl, a phenyl,
a substituted lower alkyl, or a substituted phenyl.
6. The method of claim 5, wherein each X is independently selected from the group consisting of fluorine, chlorine, and bromine.
7. The method of claim 1, wherein the compound is a
pharmaceutically acceptable hydrochloride salt.
8. The method of claim 1, wherein the compound is
selected from the group consisting of:
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